KR20140089502A - Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract - Google Patents
Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract Download PDFInfo
- Publication number
- KR20140089502A KR20140089502A KR1020140078987A KR20140078987A KR20140089502A KR 20140089502 A KR20140089502 A KR 20140089502A KR 1020140078987 A KR1020140078987 A KR 1020140078987A KR 20140078987 A KR20140078987 A KR 20140078987A KR 20140089502 A KR20140089502 A KR 20140089502A
- Authority
- KR
- South Korea
- Prior art keywords
- panax
- leaf extract
- exercise
- composition
- ginseng
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 189
- 239000000203 mixture Substances 0.000 title claims abstract description 134
- 241000208343 Panax Species 0.000 title claims abstract description 64
- 230000000694 effects Effects 0.000 title claims abstract description 54
- 238000011084 recovery Methods 0.000 title claims abstract description 15
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract 3
- 230000006872 improvement Effects 0.000 title description 8
- 230000001965 increasing effect Effects 0.000 claims abstract description 32
- 235000008434 ginseng Nutrition 0.000 claims description 119
- 244000131316 Panax pseudoginseng Species 0.000 claims description 109
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 108
- 235000002791 Panax Nutrition 0.000 claims description 56
- 210000003205 muscle Anatomy 0.000 claims description 51
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 33
- 240000004371 Panax ginseng Species 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 235000002789 Panax ginseng Nutrition 0.000 claims description 23
- 229930182494 ginsenoside Natural products 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 18
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 17
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 17
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 17
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 16
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 108010030844 2-methylcitrate synthase Proteins 0.000 claims description 13
- 108010071536 Citrate (Si)-synthase Proteins 0.000 claims description 13
- 102000006732 Citrate synthase Human genes 0.000 claims description 13
- 102000004420 Creatine Kinase Human genes 0.000 claims description 13
- 108010042126 Creatine kinase Proteins 0.000 claims description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 229940089161 ginsenoside Drugs 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 7
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 7
- 229940031439 squalene Drugs 0.000 claims description 7
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 7
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 241000190633 Cordyceps Species 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 240000005373 Panax quinquefolius Species 0.000 claims description 4
- 241000534017 Saururus chinensis Species 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229960003624 creatine Drugs 0.000 claims description 4
- 239000006046 creatine Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 235000003174 Panax japonicus Nutrition 0.000 claims description 3
- 241000168720 Panax japonicus Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 241001527087 Panax vietnamensis Species 0.000 claims description 3
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 3
- 235000003138 Panax wangianus Nutrition 0.000 claims description 3
- 241000180664 Panax wangianus Species 0.000 claims description 3
- 241000219793 Trifolium Species 0.000 claims description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 abstract description 35
- 239000008280 blood Substances 0.000 abstract description 35
- 239000000126 substance Substances 0.000 abstract description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 15
- 239000001301 oxygen Substances 0.000 abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 abstract description 15
- 238000009825 accumulation Methods 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 6
- 230000037080 exercise endurance Effects 0.000 abstract description 3
- 230000007103 stamina Effects 0.000 abstract description 2
- 230000002802 cardiorespiratory effect Effects 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 104
- 238000005259 measurement Methods 0.000 description 39
- 241000700159 Rattus Species 0.000 description 37
- 238000012360 testing method Methods 0.000 description 34
- 230000003078 antioxidant effect Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 18
- 239000003963 antioxidant agent Substances 0.000 description 17
- 239000000835 fiber Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000001590 oxidative effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 230000037147 athletic performance Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940107131 ginseng root Drugs 0.000 description 7
- 230000000386 athletic effect Effects 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002270 ergogenic effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010060891 General symptom Diseases 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 108030001204 Myosin ATPases Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101100187345 Xenopus laevis noto gene Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000006069 Panax sp Nutrition 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006388 chemical passivation reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000009943 skeletal muscle blood flow Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 241001634496 Cola nitida Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000490050 Eleutherococcus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- -1 Rg5 and Rk1 Substances 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 241000722281 Saururus Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 231100000647 material safety data sheet Toxicity 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
Description
본 연구는 21세기 프론티어연구개발사업인 자생식물이용기술개발사업단의 연구비지원[과제번호(#PF0321204-00)]에 의해 수행되었다. This research was carried out by the research funding support (# PF0321204-00) of the Natural Plant Usage Technology Development Project, a 21st Century frontier research and development project.
본 발명은 파낙스속 식물의 잎 추출물 및 파낙스속 식물의 잎 추출물 가공물의 혼합물을 유효성분으로 함유하는 운동능력 및 피로회복 증진용 조성물 및 항산화 조성물에 관한 것이다. The present invention relates to a composition for promoting exercise capacity, fatigue recovery, and antioxidant composition containing a mixture of a leaf extract of Panax spp. And a leaf extract of Panax spp. As an active ingredient.
일반적으로 근육은 지속적으로 운동하지 않을 경우 노화에 따라 근육 기능이 저하되고 근육량 및 근육신경연접(neuromuscular junction, motor unit)의 감소가 일어나 쉽게 피로를 느끼며 무기력해져서 생활의 활력이 감소됨으로써 삶의 질이 급격히 떨어진다(Dohergy TJ, J Appl. Physiol., 95:1717-1727, 2003; Eric E, et al., Physiol. Behav., 92(1-2):129-135, 2007). In general, if the muscles are not exercised continuously, the muscular function decreases due to aging, the neuromuscular junction (motor unit) decreases, and fatigue easily occurs. (Dohergy TJ, J Appl. Physiol., 95: 1717-1727, 2003; Eric E, et al., Physiol. Behav., 92 (1-2): 129-135, 2007).
이를 방지하기 위해서 저항력 운동(resistance training)과 같은 적절한 운동을 지속적으로 실시하는 것과 함께 적절한 식이 요법을 함께하는 것이 권장되고 있다. 하지만 대부분 바쁜 일상에 쫓기는 현대인의 경우 인삼, 홍삼을 포함하는 자양강장 효능을 주장하는 건강 보조제(dietary supplement)로부터 도움을 받기를 원하고 있다. 삶의 질 향상을 위해 규칙적인 운동은 현대인들에게 삶의 일부가 되었고, 운동 선수 뿐만 아니라 일반인들도 일상 생활에서 보다 많은 에너지 및 지구력을 원하고 있다. 섭식용의 다양한 제형의 인삼뿌리 추출물은 운동능력을 증진시키는데 있어서의 인삼의 효능을 입증하기 위하여 많은 연구가 수행되어온 후보물질 중 하나이다.In order to prevent this, it is recommended that proper diet is combined with proper exercise such as resistance training. However, most modern people who are chased by busy daily life want to get help from dietary supplements claiming ginseng and red ginseng effects. To improve the quality of life, regular exercise has become part of life for modern people, and not only athletes but also ordinary people want more energy and endurance in everyday life. Ginseng root extract of various formulations for feeding is one of the candidates that has been studied a lot to demonstrate the efficacy of ginseng in promoting exercise capacity.
인삼은 오래 전부터 천연 에르고제닉 에이드 (natural ergogenic aid)로 알려져 있으며, 강장효과, 항산화효과, 숙취에 대한 효과 등에 이르기까지 매우 다양한 효능들이 밝혀지고 있다 (Kim SH, et al., J Sports Med. Phys. Fitness., 45(2):178-82, 2005). 특히 파낙스 진생(Panax ginseng)은 미토콘드리아 에너지 대사를 개선시키고, 유산소 운동능력 (aereobic exercise performance)의 증진에는 진세노사이드 Rg1과 Rb1이 작용한다고 보고된 바 있다 (Wang LC, et al., Planta Med., 64(2):130-133, 1998). 또한, 인삼의 유효성분으로 알려진 진세노사이드 중 Rg3와 Re에 대한 항산화 효능에 의한 산화 스트레스 (oxidative stress) 감소 효능이 보고되어 있다 (Tian J, et al., Neurosci. Lett., 374(2):92-97, 2005; Cho WC, et al., 2006, Eur. J. Pharmacol., 550(1-3):173-179, 2006). 또한 과격한 운동을 하는 동안 혈장 크레아틴 키나아제 (CK)의 유출을 감소시켜 골격근 (skeletal muscle) 세포막 손상을 감소시켜 근육 손상을 막는다는 보고가 있다 (Hsu CC, et al., World J. Gastroenterol., 11(34):5327-5331, 2005). 인삼은 항노화, 면역력 증강, 항암, 항스트레스, 항산화 및 장기보호효과와 관련된 약리효과를 갖는 것으로 추정된다 (Gillis CN, Biochem Pharmacol., 54(1):1-8, 1997; Attele AS, et al., Biochem Pharmacol., 58(11):1685-93, 1999; Shin HR, et al., Cancer Causes Control., 11(6):565-76, 2000).Ginseng has long been known as a natural ergogenic aid and has been shown to have a wide variety of effects ranging from a tonic effect, an antioxidant effect, and a hangover effect (Kim SH, et al., J Sports Med. Phys Fitness, 45 (2): 178-82, 2005). Panax ginseng, in particular, has been reported to improve mitochondrial energy metabolism, and ginsenosides Rg1 and Rb1 have been implicated in the promotion of aerobic exercise performance (Wang LC, et al., Planta Med. , 64 (2): 130-133, 1998). In addition, antioxidative effects of ginsenosides, Rg3 and Re, which are known to be effective ingredients of ginseng, have been reported to reduce oxidative stress (Tian J, et al., Neurosci. Lett., 374 (2) : 92-97, 2005; Cho WC, et al., 2006, Eur. J. Pharmacol., 550 (1-3): 173-179, 2006). It has also been reported that during extreme exercise, the release of plasma creatine kinase (CK) is reduced to reduce damage to skeletal muscle cell membranes, thereby preventing muscle damage (Hsu CC, et al., World J. Gastroenterol., 11 (34): 5327-5331, 2005). Ginseng is presumed to have pharmacological effects related to anti-aging, immunity, anticancer, anti-stress, antioxidant and long-term protective effects (Gillis CN, Biochem Pharmacol., 54 (1): 1-8, 1997; Attele AS, et al., Biochem Pharmacol., 58 (11): 1685-93, 1999; Shin HR, et al., Cancer Causes Control., 11 (6): 565-76, 2000).
인삼 뿌리는 지구력 운동을 위한 에르고제닉 에이드로 사용되어 왔으며, 스테미너 향상 및 부상으로부터의 빠른 회복을 촉진시키기 위하여 전 세계적으로 많은 운동선수들이 섭취하여 왔다. 인삼 뿌리는 소진되기까지의 운동지속시간을 증가시키며, 말론디알데히드(MDA)는 감소시키고, CAT(catalase) 및 SOD(superoxide dismutase)는 증가시킨다. 인삼 뿌리 섭취 후 [2g씩, 1일 3회, 사무직 종사자(sedentary human)에게 투여], 소거 효소(scavenger enzymes)인 CAT 및 SOD 활성이 증가하고, MDA 레벨을 감소시키는 것으로 나타났다(J. Sports Med Phys Fitness. 2005, 45(2): 178-82).Ginseng roots have been used as ergogenic aids for endurance exercise and have been consumed by many athletes around the world to promote stamina improvement and rapid recovery from injury. Ginseng roots increase the duration of exercise until exhaustion, reduce malondialdehyde (MDA), and increase CAT (catalase) and SOD (superoxide dismutase). It has been shown that CAT and SOD activities, which are scavenger enzymes, are increased and MDA levels are lowered after administration of ginseng roots (2 g, 3 times a day, to sedentary human) (J. Sports Med Phys Fitness 2005, 45 (2): 178-82).
파낙스 노토진생은 또한 소진되기까지의 운동지속시간을 증가시킨다고 보고된 바 있다 (J Strength Cond Res., 2005 19(1): 108-14). 인삼 뿌리는 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease, COPD)환자의 폐기능을 향상시키고 운동능력을 증진시킨다고 보고되었다 (Monaldi Arch Chest Dis. 2002, 57 (5-6): 242-6). 홍삼뿌리는 런닝머신 운동시 소진하기까지 걸리는 시간을 증가시키며, 운동으로 인해 유도된 세로토닌 합성 및 트립토판 히드록실라제의 발현 증가를 막는다. 이는 홍삼이 운동하는 동안 세로토닌 레벨을 억제하는 효능을 나타냄으로써 홍삼뿌리 섭취가 에르고제닉 메커니즘으로 기능할 수 있음을 의미한다(J. Pharmacol Sci. 2003, 93(2): 218-21).Panax noto has also been reported to increase exercise duration until exhaustion (J Strength Cond Res., 2005 19 (1): 108-14). Ginseng roots have been reported to improve lung function and improve motor performance in patients with chronic obstructive pulmonary disease (COPD) (Monaldi Arch Chest Dis. 2002, 57 (5-6): 242-6). Red ginseng roots increase the amount of time it takes to run out of treadmill exercise and prevent exercise-induced synthesis of serotonin and increased expression of tryptophan hydroxylase. This suggests that red ginseng root is able to function as an ergogenic mechanism by inhibiting serotonin levels during exercise (J. Pharmacol Sci. 2003, 93 (2): 218-21).
인삼(Panax ginseng) 잎은 항산화, 혈당강하 활성이 있다고 알려져 있으며, 급격한 혈당레벨의 증가를 막을 수 있고, 그 결과 당뇨병 쥐에서 TBARS 레벨을 감소시킬 수 있다 (J Ethnopharmacol. 2005 98 (3): 245-50). 미국 인삼잎은 항당뇨 및 대사촉진 활성(anti-hyperglycemic and thermogenic activities)을 갖는다고 보고된 바 있다 (Pharmacol Res., 2004, 49(2): 113-7).Panax ginseng leaves are known to have antioxidant and hypoglycemic activity and can prevent the rapid increase in blood glucose levels and result in a decrease in TBARS levels in diabetic rats (J Ethnopharmacol. 2005 98 (3): 245 -50). American ginseng leaves have been reported to have anti-hyperglycemic and thermogenic activities (Pharmacol Res., 2004, 49 (2): 113-7).
그러나, 인삼 제품을 섭취하여 신체 지구력이 향상되었음을 증명해주는 임상적 증거는 거의 존재하지 않으며 (J Am Coll Nutr. 1998, 17 (5); 462-6, Int J Sport Nutr. 1996 6(3): 263-71; J Am Diet Assoc 1997, 97:1110-5 및 J Strength Cond Res., 2001, 15 (3): 290-5), 존재하더라도 이는 전문 운동선수를 대상으로 한 실험이거나 (Forgo I, MMW Munch Med Wochenschr., 125(38):822-4, 1983), 스포츠 코치(sports teacher)를 대상으로 한 실험이었다 (Pieralisi G, et al., Clin Ther., 13(3):373-82, 1991). 그러나, 인삼 뿌리는 축구선수들의 최대 산소섭취량(VO2max) 및 젖산 역치(LDH)에 아무 효과가 없다고 보고되었고 (Int J Sport Nutr. 1999 9(4): 371-7), 신체적으로 활동적인 타이인의 젖산 역치 및 운동수행능력을 변화시키지 않았다고 보고된 바 있으며(J Med Assoc Thai 2007 90(6): 1172-9), 이는 인삼 뿌리가 웰-피트된(well-fit) 사람의 유산소 피트니스 증강에 있어 에르고제닉한 효과를 나타내지 않음을 의미한다.However, there is little clinical evidence to prove that body endurance is improved by ingesting ginseng products (J Am Coll Nutr 1998, 17 (5); 462-6, Int J Sport Nutr 1996 6 (3): (Eg, Forgo I, and J Strength Cond Res., 2001, 15 (3): 290-5) MMW Munch Med Wochenschr., 125 (38): 822-4, 1983) and sports teachers (Pieralisi G, et al., Clin Ther., 13 (3): 373-82 , 1991). However, ginseng roots have been reported to have no effect on the maximum oxygen uptake (VO 2 max) and lactate threshold (LDH) of soccer players (Int J Sport Nutr 1999 9 (4): 371-7) (J Med Assoc Thai 2007 90 (6): 1172-9), which suggests that ginseng roots are not associated with a well-fit person's aerobic fitness It does not show an ergogenic effect in the enhancement.
인삼 뿌리는 지속 운동(resistance exercise)에 따른 동화 호르몬 상태(anabolic hormonal status)를 촉진시키지 않는다는 보고도 있으며 (J Strength Cond Res., 2002 16 (2): 179-83), 일루테로코커스(가시오사피, Eleutherococcus)는 최대하(submaximal) 및 최대 유산소운동 태스크와 관련된 대사성, 동작, 또는 심리적 파라미터에 관한 에르고제닉 효과를 뒷받침해주지 않는다고 보고되었다(Med Sci Sports Exerc. 1996, 28 (4): 482-9). 또한, 인삼에서 운동능력 효과를 얻기 위해서는 수많은 대상자들에게 오랜 기간에 걸쳐 표준화된 인삼 추출물을 하루에 2g 이상 섭취시킨 경우 인삼뿌리 추출물이 유산소 운동수행능력을 증가시킬 가능성이 있다는 연구결과가 보고된 바 있다 (Am J Clin Nutr., 2000, 72:624S-36S).It is also reported that ginseng roots do not promote anabolic hormonal status according to resistance exercise (J Strength Cond Res., 2002 16 (2): 179-83), Iluterococcus , Eleutherococcus) have not been reported to support ergogenic effects on metabolic, behavioral, or psychological parameters associated with submaximal and maximal aerobic exercise tasks (Med Sci Sports Exerc. 1996, 28 (4): 482-9 ). In addition, in order to obtain an athletic performance effect from ginseng, it has been reported that when a standardized ginseng extract is ingested more than 2 g per day for a long period of time, it is possible that the ginseng root extract may increase aerobic exercise performance (Am J Clin Nutr., 2000, 72: 624S-36S).
이와 같이 운동선수 뿐만 아니라 일반인의 운동능력 향상과 관련된 인삼의 효능을 증명하는 구체적인 연구결과는 아직 없는 실정이다.Thus, there is no specific research result that demonstrates the efficacy of ginseng in relation to improving athletic performance of athletes as well as the general public.
진세노사이드는 트리터페노이드 사포닌의 특수한 그룹으로서 아글리콘의 구조에 따라 담마란(dammarane type) 및 올레난 타입(oleanane type)의 두 그룹으로 분류될 수 있다. 진세노사이드는 파낙스속에서 특정적으로 발견되며, 150 이상의 천연 발생 진세노사이드류가 뿌리, 잎/줄기, 열매 또는 두상화(flower head)에서 분리되었다. 진세노사이드는 인삼의 효능을 나타내는 주요 활성물질인 것으로 여겨져 수많은 연구의 대상이 되어왔다. 진세노사이드는 인삼의 중요한 생리활성 성분이며, 진세노사이드의 당사슬은 생리활성과 밀접하게 연관되어 있다. 진생 사포닌(진세노사이드)는 인삼의 뿌리 및 잎에서 추출된다. 그동안 주요 진세노사이드를 보다 활성있는 마이너한 진세노사이드인 Rg3로 변환시키는 방법에 초점을 맞추어 많은 연구가 수행되었다. 진세노사이드 Rg3 및 Rg2 제조시의 어려움으로 인하여 가열, 효소 및 강산처리를 통해 화합물을 제조하여 왔다(Phytochemistry 2004, 65 (3): 337-44, Phytochemistry 2008, 69 (1): 218-24, Chem Pharm Bull 2003 51(4): 404-8).Ginsenosides are a special group of triterpenoid saponins which can be classified into two groups, dammarane type and oleanane type depending on the structure of aglycon. Ginsenosides are found specifically in the genus Panax, and over 150 naturally occurring migratory species are isolated from roots, leaves / stems, fruits or flower heads. Ginsenoside has been the subject of numerous studies because it is considered to be the main active substance showing the efficacy of ginseng. Ginsenoside is an important physiologically active ingredient of ginseng, and glycoside sugar chains are closely related to physiological activity. Fresh saponins (ginsenosides) are extracted from the roots and leaves of ginseng. A number of studies have been conducted focusing on the conversion of major ginsenosides to the more active minor ginsenosides Rg3. Due to difficulties in preparing ginsenosides Rg3 and Rg2 compounds have been prepared by heating, enzymatic and strong acid treatment (Phytochemistry 2004, 65 (3): 337-44, Phytochemistry 2008, 69 (1): 218-24, Chem Pharm Bull 2003 51 (4): 404-8).
한편, 스테로이드, 카페인, 탄산수소나트륨 및 구연산 나트륨 등과 같은 화합물을 포함하는 보조제는 일정량 이상 복용하면 운동 수행능력을 현저히 증가시킬 수 있으나 상기와 같은 약물은 치명적인 부작용을 수반하여 궁극적으로 건강을 해치게 되는 위험이 있다. On the other hand, supplements containing compounds such as steroids, caffeine, sodium hydrogencarbonate and sodium citrate may significantly increase exercise performance if taken over a certain amount, but such drugs may lead to a risk of ultimately causing health problems with fatal side effects .
따라서, 최근에는 식물 추출물과 같이 안전성이 보장된 천연물을 이용하여 기능성 보조제를 개발하고자 하는 연구가 활발히 진행되고 있으며, 예컨대 한국특허등록 제526164호에는 스쿠알렌 및 식물 추출물을 포함하는 운동수행능력 증강용 조성물이 기재되어 있다. Therefore, recently, studies for developing a functional adjuvant using natural substances with safety, such as plant extracts, have been actively conducted. For example, Korean Patent Registration No. 526164 discloses a composition for enhancing exercise performance comprising squalene and plant extract .
본 발명은 상기와 같은 요구에 의해 안출된 것으로서, 본 발명자들은 운동수행능력 및 피로회복을 효과적으로 증강시키고, 항산화 효능을 갖는, 부작용이 없는 보조제에 대해 연구하던 중, 파낙스속 식물의 잎 추출물 및 파낙스속 식물의 잎 추출물 가공물의 혼합물을 함유하는 조성물 섭취시 운동수행능력이 증가되고 혈중 피로요소의 축적이 억제됨을 확인함으로써 본 발명을 완성하였다. DISCLOSURE OF THE INVENTION The present invention has been made in view of the above needs, and the present inventors have intensively studied the adjuvant without adverse effect, which effectively enhances exercise performance and fatigue recovery, has antioxidative effect, The present inventors have completed the present invention by confirming that the exercise performance is increased and the accumulation of blood fatigue elements is suppressed when the composition containing the mixture of the leaf extract composition of the plant is inhibited.
상기 과제를 해결하기 위해, 본 발명은 파낙스속 식물의 잎 추출물 및 파낙스속 식물의 잎 추출물 가공물의 혼합물을 유효성분으로 함유하는 운동능력 및 피로회복 증진용 조성물 및 항산화 조성물을 제공한다. In order to solve the above problems, the present invention provides a composition for promoting exercise capacity, fatigue recovery and an antioxidant composition, which comprises a mixture of leaf extract of Panax spp. And leaf extract of Panax spp. As an active ingredient.
바람직하게, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물 중 총 진세노사이드의 함량은 30wt% 이상, 바람직하게는 40wt% 이상이며, 사포닌류를 90%이상 함유한다. Preferably, the total ginsenoside content in the mixture of the leaf extract of Panax ginseng plant and the leaf extract is at least 30 wt%, preferably at least 40 wt%, and contains at least 90% of saponins.
바람직하게, 본 발명은 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 프로토파낙사트리올의 3-O-글리코시드 유도체 및 프로토파낙사디올의 3-O-글리코시드 유도체를 포함하는 조성물을 제공한다.Preferably, the present invention relates to a composition comprising a leaf extract of Panax spp. And a mixture of the leaf extract thereof, comprising a 3-O-glycoside derivative of protopanaxatriol and a 3-O-glycoside derivative of protopanaxadiol Lt; / RTI >
본 발명의 일 구체예에 따르면, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 진세노사이드 Rg3, Rg5 및 Rk1으로 구성된 군에서 선택된 하나 이상의 성분을 함유하는 운동능력 증진용, 피로회복 증진용 또는 항산화 조성물이 제공된다.According to one embodiment of the present invention, the leaf extract of Panax ginseng plant and the mixture of the leaf extract product thereof contains at least one ingredient selected from the group consisting of ginsenosides Rg3, Rg5 and Rk1, Or an antioxidant composition is provided.
본 발명에 따른 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물에서, 상기 추출물 중에 Rg3, Rg5 및 Rk1 성분의 총함량은 바람직하게 5wt%이상, 더 바람직하게 10wt%이상이다.In the mixture of the leaf extract of the Panax ginseng plant and the product of the leaf extract thereof according to the present invention, the total content of the Rg3, Rg5 and Rk1 components in the extract is preferably 5 wt% or more, more preferably 10 wt% or more.
본 발명에 따른 조성물에서, 상기 파낙스속 식물의 잎 추출분말 및 그 잎 추출분말 가공물은 1:0.1 내지 10의 비율로 혼합될 수 있으며, 바람직하게는 1:0.1 내지 5, 더 바람직하게는 1:0.1 내지3, 보다 더 바람직하게는 1:0.5 내지 2의 비율로 혼합될 수 있다. In the composition according to the present invention, the leaf extract powder of the Panax ginseng plant and the leaf extract powder thereof may be mixed at a ratio of 1: 0.1 to 10, preferably 1: 0.1 to 5, more preferably 1: 0.1 to 3, and even more preferably 1: 0.5 to 2.
본 발명에서, 상기 파낙스속 식물은 파낙스 진생(Panax ginseng), 파낙스 자포니쿰(Panax japonicum), 파낙스 퀸크폴리움(Panax quinquefolium), 파낙스 노토진생(Panax notoginseng), 삼엽삼 (Panax trifolium) 및 파낙스 슈도진생(Panax pseudoginseng), 베트남삼(Panax vietnamensis), 파낙스 엘레가티오르(Panax elegatior), 파낙스 완지아누스 (Panax wangianus) 및 파낙스 비핀라티피두스(Panax bipinratifidus)로 이루어진 군에서 선택될 수 있다.In the present invention, the plant belonging to the genus Panax is called Panax ginseng), Panax party pony Qom (Panax japonicum), Panax kwinkeu poly Stadium (Panax quinquefolium), Noto Panax Ginseng (Panax notoginseng), three yeopsam (Panax trifolium) and Panax pseudo-ginseng (Panax pseudoginseng), Vietnam, three (Panax vietnamensis ), Panax elegatior , Panax wangianus , and Panax bipinratifidus .
본 발명의 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물에는 스쿠알렌, 삼백초 수추출물, 오가피 수추출물, 동충하초 수추출물, 콜라넛 분말 또는 추출물, 비타민류, 미네랄류, 타우린, 포스파티딜콜린, 글루타민, L-아르기닌 및 L-카르니틴으로 이루어진 군으로부터 선택되는 하나 이상의 성분을 추가로 포함할 수 있다.The mixture of the leaf extract of the Panax ginseng plant and the leaf extract includes squalene, Saururus chinensis extract, Ogassi water extract, Cordyceps juice extract, Collagen powder or extract, Vitamins, Minerals, Taurine, Phosphatidylcholine, Glutamine, L - arginine, and L-carnitine.
본 발명에 따른 조성물은 섭취시 운동수행시간을 증진시키며 혈중 피로물질의 축적을 억제하는 효과 및 항산화 효능이 있을 뿐만 아니라 최대 산소섭취량에 따른 유산소 운동 능력 즉, 심폐운동 지구력이 향상되는 효과가 있기 때문에 체력 및 운동능력 증진에 유용하며 또한 사람이 섭취하더라도 안전하다.The composition according to the present invention has an effect of enhancing exercise performance time during ingestion, inhibiting the accumulation of blood fatigue substances and antioxidative effect, and improving aerobic exercise ability according to the maximum oxygen uptake, that is, cardiopulmonary exercise endurance It is useful for improving physical fitness and athletic ability, and is safe even if ingested by a person.
도 1은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 2주 후의 래트의 최대 주행거리 측정 결과를 도시한 것이다.
도 2는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 8주 후의 래트의 최대 주행거리 측정 결과를 도시한 것이다.
도 3은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 6주 후의 래트의 최대 주행거리 측정 결과를 도시한 것이다.
도 4는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 9주 후의 래트의 최대 주행거리 측정 결과를 도시한 것이다.
도 5는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 2주 운동 후의 래트의 혈중 CK(creatine kinase) 측정 결과를 도시한 것이다.
도 6은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 혈중 LDH 측정 결과를 도시한 것이다.
도 7은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 8주 운동 후의 래트의 혈중 LDH 측정 결과를 도시한 것이다.
도 8은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 근육 중 LDH 측정 결과를 도시한 것이다.
도 9는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 혈중 젖산 측정 결과를 도시한 것이다.
도 10은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 혈중 젖산 측정 결과를 도시한 것이다.
도 11은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 혈중 코르티코스테론 측정 결과를 도시한 것이다.
도 12는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 혈중 코르티코스테론 측정 결과를 도시한 것이다.
도 13은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 근육 중 CS 활성도 측정결과를 도시한 것이다.
도 14는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 근육 중 CS 활성도 측정 결과를 도시한 것이다.
도 15는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 혈중 NO 측정 결과를 도시한 것이다.
도 16은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 비운동군 래트의 근육 중 NO 측정 결과를 도시한 것이다.
도 17은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물을 투여한 운동군 래트에서 운동 2주차 운동전 채혈한 혈액에서 NO 함량을 측정한 결과를 도시한 것이다.
도 18은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물을 투여한 운동군 래트에서 운동 2주차 운동 후 채혈한 혈액에서 NO 함량을 측정한 결과를 도시한 것이다.
도 19는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 근육 중 NO 측정 결과를 도시한 것이다.
도 20은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 근육 중 SOD 저해율(%) 측정 결과를 도시한 것이다.
도 21은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 운동군 래트의 근육 중 GPx 측정 결과를 도시한 것이다.
도 22는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 가자미근(soleus muscle)에서의 ATPase 테스트 결과를 도시한 것이다.
도 23은 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물의 레드 장딴지근(red gastrocnemius muscle)에서의 ATPase 테스트 결과를 도시한 것이다.
도 24는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물을 투여한 군에서 VO2 max의 변화추이를 측정한 결과를 도시한 것이다.
도 25는 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물을 투여한 군에서 AT값의 변화를 측정한 결과를 도시한 것이다.FIG. 1 shows the results of measurement of the maximum range of the rat after two weeks of exercise in a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 2 shows the results of measurement of the maximum travel distance of a rat after 8 weeks of exercise in a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 3 shows the results of measurement of the maximum travel distance of a rat after 6 weeks in a non-rain group of a mixture of a ginseng leaf extract and a ginseng leaf extract product.
FIG. 4 shows the results of measurement of the maximum distance traveled by the rat after 9 weeks of the non-raising group of the mixture of the ginseng leaf extract and the ginseng leaf extract product.
FIG. 5 shows blood creatine kinase (CK) measurement results of rats after two weeks of exercise in a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 6 shows blood LDH measurement results of a non-osmotic rat mixture of a ginseng leaf extract and a ginseng leaf extract product.
FIG. 7 shows the results of blood LDH measurement in rats after 8 weeks of exercise in a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 8 shows the results of LDH measurement in the muscle of the exercise group of the mixture of the ginseng leaf extract and the ginseng leaf extract composition.
FIG. 9 shows the results of blood lactate measurement of non-rabbit rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 10 shows blood lactic acid measurement results of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 11 shows the blood corticosterone measurement results of non-rabbit rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 12 shows blood corticosterone measurement results of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 13 shows the results of measurement of CS activity in muscle of non-rabbit rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 14 shows the results of measurement of CS activity in muscles of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract product.
Fig. 15 shows the NO measurement results of non-rabbit rats in a mixture of ginseng leaf extract and ginseng leaf extract product.
FIG. 16 shows the results of NO measurement in muscle of non-rabbit rats of a mixture of ginseng leaf extract and ginseng leaf extract product.
FIG. 17 shows the results of measurement of NO content in the blood collected before
FIG. 18 shows the results of measurement of NO content in blood collected from
FIG. 19 shows the results of NO measurement in muscle of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 20 shows the results of SOD inhibition (%) measurement in muscle of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 21 shows the results of GPx measurement in muscle of exercise group rats of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 22 shows ATPase test results in a soleus muscle of a mixture of ginseng leaf extract and ginseng leaf extract.
FIG. 23 shows ATPase test results on a red gastrocnemius muscle of a mixture of ginseng leaf extract and ginseng leaf extract product.
24 shows the results of measurement of the change in VO 2 max in the group administered with the mixture of the ginseng leaf extract and the ginseng leaf extract composition.
25 shows the results of measuring changes in AT values in a group administered with a mixture of ginseng leaf extract and ginseng leaf extract.
본 발명의 목적을 달성하기 위하여, 본 발명은 파낙스 속 식물의 잎 추출물 및 그 잎 추출물 가공물의 혼합물을 유효성분으로 함유하는 운동능력 및 피로회복 증진용 조성물 및 항산화 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides a composition for promoting exercise capacity, fatigue recovery and an antioxidant composition comprising a mixture of a leaf extract of Panax ginseng plant and a leaf extract composition thereof as an active ingredient.
본 발명의 일 구현예에 따른 조성물에서, 파낙스속 식물의 잎 추출물 중 총 진세노사이드의 함량은 30wt% 이상, 바람직하게는 40wt% 이상이며, 사포닌류를 90%이상 함유한다. 진세노사이드의 총함량비가 상기한 범위 이상일 때 운동능력 증진, 피로회복 촉진, 항산화 효능의 측면에서 우수한 효과를 얻을 수 있다.In the composition according to one embodiment of the present invention, the total ginsenoside content of the leaf extract of the Panax ginseng plant is 30 wt% or more, preferably 40 wt% or more, and 90 wt% or more of saponins. When the total content ratio of ginsenoside is more than the above range, excellent effects can be obtained in terms of exercise capacity, fatigue recovery, and antioxidant efficacy.
본 발명의 바람직한 구체예에 따르면, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 프로토파낙사트리올의 3-O-글리코시드 유도체 및 프로토파낙사디올의 3-O-글리코시드 유도체를 포함하는 조성물을 제공하며, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물 중 프로토파낙사트리올의 3-O-글리코시드 유도체 대 프로토파낙사디올의 3-O-글리코시드 유도체의 함량비는 1: 0.1~1.5 이고, 더 바람직하게는 1:0.5~1.5 이며, 보다 더 바람직하게는 1:0.7~1.5이다. 여기에서, 프로토파낙사트리올의 3-O-글리코시드 유도체로는 Re, Rg1, Rg2등이 있으며, 프로토파낙사디올의 3-O-글리코시드 유도체로는 Rb1, Rb2, Rb3, Rc, Rd, Rg3(R,S), Rg5, Rk1등이 있다. 상기 트리올 대 디올의 함량비가 상기한 범위내에 존재할 때, 운동능력 증진, 피로회복 촉진, 항산화 효능의 측면에서 우수한 효과를 얻을 수 있다.According to a preferred embodiment of the present invention, a mixture of the leaf extract of Panax spp. And the extract of the leaf extract comprises 3-O-glycoside derivative of protopaxanthriol and 3-O-glycoside derivative of protopanaxadiol O-glycoside derivative of protopanaxatriol versus a 3-O-glycoside derivative of protopanaxadiol in a mixture of leaf extract of Panax spp. The content ratio is 1: 0.1 to 1.5, more preferably 1: 0.5 to 1.5, still more preferably 1: 0.7 to 1.5. Examples of 3-O-glycoside derivatives of protopanaxatriol include Re, Rg1, and Rg2. Examples of 3-O-glycoside derivatives of protopanaxadiol include Rb1, Rb2, Rb3, Rc, and Rd , Rg3 (R, S), Rg5, Rk1, and the like. When the content ratio of the triol to the diol is within the above range, excellent effects can be obtained in terms of exercise capacity, acceleration of fatigue recovery, and antioxidant efficacy.
본 발명의 일 구현예에 따른 조성물에서, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 진세노사이드 Rg3, Rg5 및 Rk1으로 구성된 군에서 선택된 하나 이상의 성분을 함유한다.In the composition according to an embodiment of the present invention, the leaf extract of Panax spp. And the mixture of the leaf extract thereof contains at least one ingredient selected from the group consisting of ginsenosides Rg3, Rg5 and Rk1.
본 발명의 일 구현예에 따른 조성물에서, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 Rg3, Rg5 및 Rk1과 같은 프로토파낙사디올류(protopanaxadiols)을 총 추출물 중량의 5% 이상의 함량비율로 함유한다. 또한, 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물 양자의 혼합물은 Rg3, Rg5 및 Rk1과 같은 프로토파낙사디올류(protopanaxadiols)을 총 추출물 중량의 10%이상 함유한다. 상기 Rg3, Rg5 및 Rk1의 총함량비가 상기한 범위내에 존재할 때, 운동능력 증진, 피로회복 촉진, 항산화 효능의 측면에서 우수한 효과를 얻을 수 있다.In a composition according to an embodiment of the present invention, the leaf extract of Panax spp. And the mixture of the leaf extracts thereof contains protopanaxadiols such as Rg3, Rg5 and Rk1 in an amount of not less than 5% . In addition, a mixture of both the leaf extract of Panax sp. And the leaf extract thereof contains protopanaxadiols such as Rg3, Rg5 and Rk1 in an amount of 10% or more of the total extract weight. When the total content ratio of Rg3, Rg5, and Rk1 is within the above range, excellent effects can be obtained in terms of exercise capacity, acceleration of fatigue recovery, and antioxidant efficacy.
하기 표1은 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물 (UG0712)의 진세노사이드 함량을 시판중인 인삼제품과 비교한 결과를 나타낸 것이며, 본 발명의 파낙스속 식물의 잎 추출물은 시판중인 다른 인삼제품에 비하여 진세노사이드 함량이 현저하게 높음을 알 수 있다.Table 1 below shows the results of comparing the ginsenoside content of the mixture of the leaf extract of Panax ginseng plant and the product of the leaf extract thereof (UG0712) with commercially available ginseng products. The leaf extract of Panax ginseng according to the present invention is commercially available The content of ginsenoside is remarkably higher than that of other ginseng products.
본 발명에 따른 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물 양자의 혼합물 중에 포함된 Rg3, Rg5 및 Rk1과 같은 프로토파낙사디올류(protopanaxadiols)는 하기 표2에 도시된 바와 같은 구조 및 물리화학적 특징을 갖는다.Protopanaxadiols, such as Rg3, Rg5 and Rk1, contained in the mixture of both the leaf extract of Panax ginseng plant and the leaf extract thereof according to the present invention have the structural and physicochemical properties as shown in Table 2 below .
상기 파낙스속 식물은 파낙스 진생(Panax ginseng), 파낙스 자포니쿰(Panax japonicum), 파낙스 퀸크폴리움(Panax quinquefolium), 파낙스 노토진생(Panax notoginseng), 삼엽삼 (Panax trifolium) 및 파낙스 슈도진생(Panax pseudoginseng), 베트남삼(Panax vietnamensis), 파낙스 엘레가티오르(Panax elegatior), 파낙스 완지아누스 (Panax wangianus) 및 파낙스 비핀라티피두스(Panax bipinratifidus) 등일 수 있으나, 이에 제한되지 않는다. The Panax genus plant is Panax ginseng (Panax ginseng), Panax party pony Qom (Panax japonicum), Panax kwinkeu poly Stadium (Panax quinquefolium), Noto Panax Ginseng (Panax notoginseng), three yeopsam (Panax trifolium) and Panax pseudo-ginseng (Panax pseudoginseng), Vietnam, three (Panax vietnamensis ), Panax elegatior , Panax wangianus ) and Panax bifunlatipidus ( Panax bipinratifidus ), and the like.
본 발명의 일 구현예에 따른 조성물에서, 상기 파낙스속 식물의 잎 추출물 및 그 가공물의 혼합물은 분말 형태일 수 있으나, 이에 제한되지 않는다. 추출물의 분말 형태는 파낙스속 식물의 잎 추출물을 동결건조, 열풍건조, 전자파에 의한 건조 등의 방법을 사용하여 제조될 수 있다. In the composition according to an embodiment of the present invention, the leaf extract of the Panax ginseng plant and the mixture of the processed products may be in powder form, but are not limited thereto. The powder form of the extract can be prepared by a method such as lyophilization, hot air drying or electromagnetic wave drying of a leaf extract of a plant of the genus Panax.
본 발명의 일 구현예에 따른 조성물에서, 상기 파낙스속 식물의 잎 추출분말 및 파낙스속 식물의 잎 추출분말 가공물은 1:0.1 내지 10의 비율로 혼합될 수 있으며, 바람직하게는 1:0.1 내지 5, 더 바람직하게는 1:0.1 내지 3, 더 바람직하게는 1:0.5 내지 2의 비율로 혼합될 수 있다. In the composition according to an embodiment of the present invention, the leaf extract powder of the Panax plant and the leaf extract powder composition of the Panax plant can be mixed at a ratio of 1: 0.1 to 10, preferably 1: 0.1 to 5 , More preferably from 1: 0.1 to 3, and still more preferably from 1: 0.5 to 2.
본 발명의 일 구현예에 따른 조성물에서, 파낙스속 식물의 잎 추출 분말 및 파낙스속 식물의 잎 추출 분말의 가공물의 혼합물은 하기와 같은 단계 즉,In a composition according to an embodiment of the present invention, a mixture of leaf extract powder of Panax spp. And leaf extract powder of Panax spp.
(a) 파낙스속 식물의 잎에 추출 용매를 첨가하여 환류추출한 후, 동결건조시켜 파낙스속 식물의 잎 추출 분말을 수득하는 단계;(a) adding an extraction solvent to the leaf of a plant of the genus Panax, refluxing the extract, and lyophilizing to obtain a leaf extract powder of a plant of the genus Panax;
(b) 상기 수득된 추출 분말에 물과 빙초산을 첨가하고 60~100℃에서 교반하면서 가공반응을 수행한 후 건조시켜 파낙스속 식물의 잎 추출 분말의 가공물을 수득하는 단계; 및 (b) adding water and glacial acetic acid to the obtained extract powder, performing a processing reaction at 60 to 100 ° C with stirring, and then drying to obtain a workpiece of a leaf extract powder of Panax ginseng; And
(c) 상기 (a) 단계에서 수득된 파낙스속 식물의 잎 추출 분말과 (b) 단계에서 수득된 파낙스속 식물의 잎 추출 분말의 가공물을 혼합하는 단계:(c) mixing the leaf extract powder of the Panax ginseng plant obtained in the step (a) and the leaf extract powder of the Panax ginseng plant obtained in the step (b)
를 거쳐 수득될 수 있다.≪ / RTI >
상기 추출 용매는 물, C1 -4 알코올, 또는 이들의 혼합용매일 수 있으며, 상기 알코올은 바람직하게는 에탄올이며, 더욱 바람직하게는 70% 에탄올이다. The extraction solvent may be water, C 1 -4 alcohol, or a mixture thereof, and the alcohol is preferably ethanol, more preferably 70% ethanol.
본 발명의 조성물은 상기 파낙스속 식물의 잎 추출물 및 파낙스속 식물의 잎 추출물 가공물의 혼합물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. The composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in the mixture of the leaf extract of the Panax spp. And the leaf extract of Panax spp.
본 발명의 일 구현예에 따른 조성물은 스쿠알렌, 삼백초 수추출물, 오가피 수추출물, 동충하초 수추출물, 콜라넛 분말 또는 추출물, 비타민류, 미네랄류, 타우린, 크레아틴, 포스파티딜콜린, 글루타민, L-아르기닌 및 L-카르니틴으로 이루어진 군으로부터 선택되는 하나 이상의 성분을 추가로 포함할 수 있다. The composition according to one embodiment of the present invention may further comprise at least one selected from the group consisting of squalene, Saururus ricinus extract, Ogassi water extract, Cordyceps juice extract, Collagen powder or extract, Vitamins, Minerals, Taurine, Creatine, Phosphatidylcholine, Glutamine, ≪ RTI ID = 0.0 > and / or < / RTI >
삼백초, 오가피 및 동충하초의 수추출물은 공지의 방법에 따라 제조하여 사용할 수 있거나 또는 상기 수추출물들은 시판되는 것을 구입하여 사용할 수 있다.The water extracts of Saururus chinensis, Ogapi and Cordyceps can be prepared and used according to known methods, or the commercially available water extracts can be purchased and used.
스쿠알렌은 6개의 이중결합을 가진 고도 불포화 탄화수소로서 일반적으로 심해상어의 간유에 추출하여 정제함으로써 제조된다. 스쿠알렌의 생리활성으로는 산소공급작용 및 살균작용 등이 있다. 특히, 스쿠알렌은 인체의 물 분자에서 수소를 결합하고 산소를 방출함으로써 방출된 산소가 체내의 세포에 산소를 공급하여 세포를 활성화시킨다고 알려져 있다. Squalene is a polyunsaturated hydrocarbons with six double bonds and is generally prepared by extraction and purification in deep sea shark liver oil. Physiological activities of squalene include oxygen supply action and sterilization action. In particular, it is known that squalene binds hydrogen in water molecules of human body and releases oxygen to release oxygen, which activates cells by supplying oxygen to the cells in the body.
삼백초는 오래살이풀로서 그 약리작용이 매우 다양하다. 즉, 변비, 당뇨병, 간장병, 암, 고혈압, 심장병, 부인병 및 신장병과 같은 성인병의 예방과 치료에 주목할 만한 효과가 있는 것으로 알려져 있다. Saururus chinensis is a long-lived grass and its pharmacology is very diverse. That is, it is known that there is a remarkable effect in the prevention and treatment of adult diseases such as constipation, diabetes, liver disease, cancer, hypertension, heart disease, gynecological disease and kidney disease.
오가피는 두릅나무과 낙엽관목인 가시오갈피의 뿌리와 나무껍질을 건조한 것을 말하며 양위, 관절염, 요통, 퇴행성 관절염 증후군, 수종, 각기, 타박상 및 종창 등에 처방하는 것으로 알려져 있다. Ogapi is a dried plant of Araliaceae and a deciduous shrub of Asteraceae and has been known to prescribe bark, arthritis, back pain, degenerative arthritis syndrome, species, bruises, bruises and swelling.
동충하초는 자낭균류에 속하는 소형 버섯류로서 대부분 곤충에 기생하여 숙주가 되는 곤충의 시체에 자실체를 낸다. 상기 동충하초는 기관지를 정화하고 혈관 내에 부착된 불순물을 제거하며 심장의 수축력을 강화하는 생리활성을 가진 것으로 알려져 있다. 또한, 세포의 활성화와 회복, 면역력 강화, 혈당치의 정상화, 빈혈 및 비만에 효과가 있는 것으로 알려져 있다. Cordyceps is a small mushroom belonging to the acanthaceous fungus, most of which is parasitic on insects and produces fruiting bodies on insect bodies that become host. It is known that the Chinese caterpillar fungus has physiological activity to purify the bronchi, remove impurities adhering to the blood vessel, and enhance the contraction force of the heart. It is also known to be effective in cell activation and recovery, immunity enhancement, normalization of blood glucose levels, anemia and obesity.
상기 타우린, 크레아틴, 글루타민, L-아르기닌 및 L-카르니틴과 같은 아미노산류는 운동 후 근육의 피로 회복을 도우며 직접 에너지원으로 사용되기도 한다. Amino acids such as taurine, creatine, glutamine, L-arginine and L-carnitine help muscle fatigue after exercise and are also used as direct energy sources.
포스파티딜콜린은 지방, 인 및 질소의 화합물로서 난황, 콩기름, 간, 뇌 등에 다량 존재한다. 세포막 구성의 중요한 성분 중 하나이며, 피로회복에 효과적으로 알려져 있다. Phosphatidylcholine is a compound of fat, phosphorus, and nitrogen, and exists in large amounts in egg yolk, soybean oil, liver, and brain. It is one of the important components of cell membrane composition and is known effectively for fatigue recovery.
콜라넛은 벽오동과(Sterculiaceae)에 속하며 콜라 아쿠미나타(Cola acuminata)와 콜라 니티다(C. nitida)의 카페인이 들어있는 열매를 말한다. 아프리카 열대지역이 원산지이며 알코올 성분이 없는 음료와 의약품의 원료로 사용되고 있고 약물중독, 숙취 및 설사를 치료하는 생약으로 쓰이고 있다. 본 발명의 조성물에 포함되는 콜라넛은 추출물의 형태이거나 분말 형태일 수 있다. Collaunut refers to the caffeine-bearing fruit of Cola acuminata and C. nitida belonging to Sterculiaceae. It is the origin of the African tropics and is used as a raw material for beverages and medicines without alcohol, and is used as a medicinal herb to treat drug addiction, hangover and diarrhea. The collagen contained in the composition of the present invention may be in the form of an extract or in powder form.
본 발명에 사용되는 비타민류로는 비타민 B1, 비타민 B2, 비타민 B6, 니코틴산아미드, 비타민 C가 있고, 미네랄류로는 MgCl2, KCl, NaCl, Ca-락테이트, 구연산암모늄철 등이 있는데 이들을 조합하여 사용할 수 있다. Examples of the vitamins used in the present invention include vitamin B 1 , vitamin B 2 , vitamin B 6 , nicotinic acid amide and vitamin C, and minerals include MgCl 2 , KCl, NaCl, Ca-lactate and ammonium citrate These can be used in combination.
본 발명의 조성물은 운동능력 및 피로회복 증진용 조성물 및 산화반응 억제용 조성물로 이용될 수 있다. The composition of the present invention can be used as a composition for promoting exercise capacity and fatigue recovery and a composition for inhibiting oxidation reaction.
상기 조성물의 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다. For administration of the composition, in addition to the active ingredient described above, one or more pharmaceutically acceptable carriers may be prepared. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using appropriate methods in the art or by the method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA.
본 발명의 조성물은 목적하는 방법에 따라 비경구 투여(예를 들어 정맥 내, 피하, 복강 내 또는 국소에 적용)하거나 경구 투여할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) orally, and the dose may be appropriately determined depending on the body weight, age, sex, The range varies depending on diet, administration time, method of administration, excretion rate, and severity of the disease.
본 발명의 일 구현예에 따른 조성물에서, 상기 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은 운동능력 증진, 피로물질의 축적 억제 효과 및 항산화 효과가 있으며, 최대 산소섭취량에 따른 유산소 운동 능력 즉, 심폐운동 지구력이 향상되는 효과가 있기 때문에 체력 및 운동능력 증진에 유용하다. In the composition according to an embodiment of the present invention, the leaf extract of the plant of the Panax sp. And the mixture of the leaf extract thereof has the effect of enhancing the exercise capacity, inhibiting accumulation of fatigue substances and antioxidant effect, It is useful for improving physical fitness and athletic ability because it has the ability to improve the CPR endurance.
보다 자세하게 본 발명에 따른 파낙스속 식물의 잎 추출물 및 그 잎 추출물의 가공물의 혼합물은, 동물의 운동능력을 증진시키고, CK(creatine kinase), LDH(lactate dehydrogenase), 젖산(lactate), 코르티코스테론(corticosterone) 등과 같은 피로인자의, 운동으로 인한 근육 및/또는 혈중 축적을 억제하며, 운동능력 향상과 관련 있는 type I 근육 증가 또는 CS(citrate synthase) 활성도 증가를 통해 운동수행능력을 증진시키고, NO(nitric oxide) 억제, SOD(syperoxide dismutase) 산화 억제율 증가, GPx(glutathione peroxidase)의 활성 증가를 통해 산화반응을 억제하는 효능이 있으며, VO2 max 증대, AT (Anaerobic Threshold) 증대 효과를 통해 운동능력을 개선시킬 수 있다.In more detail, the leaf extract of Panax ginseng plant and the mixture of the leaf extract thereof according to the present invention can be used for improving the exercise ability of an animal and for improving the animal's ability to produce creatine kinase, lactate dehydrogenase (LDH), lactate, corticosterone and the like, increase the exercise performance by inhibiting muscle and / or blood accumulation due to exercise, increase type I muscle or CS (citrate synthase) It has an effect of suppressing the oxidation reaction by inhibiting nitric oxide, increasing the inhibition rate of SOD (syperoxide dismutase) oxidation, increasing the activity of GPx (glutathione peroxidase), increasing the VO 2 max and increasing the anaerobic threshold (AT) Can be improved.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
실시예Example
실험예Experimental Example 1. 예비과정 1. Preliminary Course
(1) 실험 동물 입수, 검역 및 순화 (1) Obtaining, quarantining and purification of experimental animals
7주령 SD 래트를 입수하여, 입수시 모든 동물의 일반건강상태에 대한 수의학적 검역을 실시하였다. 시험을 실시하는데 적합하고 건강한 동물을 선발하기 위하여 약 7일간의 순화기간을 거쳤으며, 실험동물은 22±2℃의 온도 및 50±20%의 습도, 12hr/day/night 조건에서 사육되었다.Seven-week-old SD rats were obtained and veterinary quarantine was conducted on the general health status of all animals at the time of arrival. Experimental animals were housed at a temperature of 22 ± 2 ° C and a humidity of 50 ± 20% at 12hr / day / night for the selection of healthy animals.
(2) 실험동물 선발 및 군 분리 (2) Selection of experimental animals and group separation
운동을 하는데 무리가 없는 건강한 개체로서 일정한 운동능력을 가진 개체를 선발하기 위하여, 군 분리 이전에 순화 기간을 거친 동물에 대해 런닝머신(treadmill) 운동을 시켜 아웃라이어(outlier)를 제거한 후 체중을 기초로 무작위적으로 군 배치하여 군 분리하였다. In order to select individuals with a certain motor ability as healthy individuals without exercise, a treadmill exercise was performed on the animals that had undergone the refinement period before the separation, and then the outliers were removed, Were randomly grouped and grouped.
(3) 개체식별(3) Identification of individual
사육상자에는 시험번호, 성별, 군 번호, 개체번호, 투여량, 시험기간 및 시험책임자 명을 기재한 개체식별 카드를 부착하였다. 개체식별은 유성매직을 이용한 꼬리 마킹(tail marking)법을 사용하였다.The breeding box was fitted with an individual identification card containing the test number, sex, group number, individual number, dose, duration of the test, and the name of the investigator. Individual identification was done by tail marking method using oil magic.
(4) 시험물질의 제조(4) Preparation of test materials
1) 인삼근 농축액 분말의 제조 1) Preparation of ginseng muscle concentrate powder
인삼근(Panax ginseng root) 1kg을 70% 에탄올 10L를 첨가하여 7시간씩 3회 환류추출하였다. 1, 2, 3차 추출액을 혼합하여 5 ㎛ 필터 하우징을 이용하여 여과하였다. 여액(28L)은 감압농축기를 이용하여 농축하여 20 Brix%가 되게 하였다. 농축액을 동결건조용 트레이에 1 kg씩 넣고 -70℃의 동결건조기(deep freezer)에서 48시간 동결시켰다. 동결이 완료된 농축액을 동결건조기에 넣고 48시간 동결건조하여 인삼농축액 분말 542 g(수율: 54.2%)을 얻었다. One kilogram of ginseng root (Panax ginseng root) was refluxed three times for 7 hours by adding 10 L of 70% ethanol. The 1st, 2nd and 3rd extracts were mixed and filtered using a 5 ㎛ filter housing. The filtrate (28 L) was concentrated to 20 Brix% using a vacuum concentrator. 1 kg of the concentrate was placed in a freeze-drying tray and freeze-dried in a deep freezer at -70 ° C for 48 hours. After the freezing was completed, the concentrate was placed in a freeze dryer and lyophilized for 48 hours to obtain 542 g of a concentrated ginseng powder (yield: 54.2%).
2) 인삼잎 추출분말의 제조 2) Preparation of ginseng leaf extract powder
인삼잎(Panax ginseng leaf) 2.5 kg을 70% 에탄올 25L를 첨가하여 5시간 환류추출하였다. 추출액을 5 ㎛ 필터 하우징을 이용하여 여과하였다. 여액(22L)은 감압농축기를 이용하여 농축하여 15Brix%가 되게 하였다. 농축액을 동결건조용 트레이에 1 kg씩 넣어 -70℃의 동결건조기 (deep freezer)에서 48시간 동결시켰다. 동결이 완료된 농축액을 동결건조기((주) 일신랩, 한국)에 넣고 48시간 동결건조하여 인삼잎 추출분말 354g(수율: 14.16%)을 얻었다. 2.5 kg of Panax ginseng leaf was added with 25 L of 70% ethanol and refluxed for 5 hours. The extract was filtered using a 5 [mu] m filter housing. The filtrate (22L) was concentrated to 15 Brix% using a vacuum concentrator. 1 kg of the concentrate was placed in a freeze-drying tray and frozen for 48 hours in a deep freezer at -70 ° C. After the freezing was completed, the concentrate was placed in a freeze dryer (Ilshin Lab, Korea) and lyophilized for 48 hours to obtain 354 g of ginseng leaf extract powder (yield: 14.16%).
3) 인삼잎 추출분말 가공물의 제조 3) Preparation of ginseng leaf extract powder
상기 방법 2)에 의해 제조된 인삼잎 추출분말(100 g)을 둥근바닥 플라스크(2L)에 넣는다. 그리고 정제수 360~380mL와 빙초산 20~40 ml(5~10%)를 첨가하였다. 혼합물을 60~100℃에서 2~6시간 동안 교반하면서 가열을 실시하였다. 추출액(400 ml)은 감압농축기를 이용하여 20 Brix%가 되게 농축하였다. 농축액을 동결건조 트레이에 넣어 -70℃ 동결건조기(deep freezer)에서 48시간 동결시켰다. 동결이 완료된 농축액을 동결건조기에 넣고 48시간 동결건조하여 인삼잎 추출물 가공물 92.5g(92.5%)을 얻었다.The ginseng leaf extract powder (100 g) prepared by the above method 2) is put into a round bottom flask (2L). 360 ~ 380 mL of purified water and 20 ~ 40 mL (5 ~ 10%) of glacial acetic acid were added. The mixture was heated at 60 to 100 DEG C for 2 to 6 hours with stirring. The extract (400 ml) was concentrated to 20 Brix% using a vacuum concentrator. The concentrate was placed in a freeze-dried tray and frozen for 48 hours in a -70 ° C deep freezer. The frozen concentrate was placed in a freeze dryer and lyophilized for 48 hours to obtain 92.5 g (92.5%) of ginseng leaf extract.
4) 인삼잎 추출물과 인삼잎 추출물 가공물의 혼합물 제조 4) Manufacture of mixture of ginseng leaf extract and ginseng leaf extract
상기 방법 2)에 의해 제조된 인삼잎 추출물 350 g과 방법 3)에 의해 제조된 인삼잎 추출물 가공물 650 g을 리본형혼합기를 이용하여 20분간 혼합하여 990g(수율: 99%)의 혼합물을 얻었다. 350 g of the ginseng leaf extract prepared by the above method 2) and 650 g of the ginseng leaf extract manufactured by the method 3) were mixed for 20 minutes using a ribbon type mixer to obtain 990 g (yield: 99%) of a mixture.
각각의 시험물질의 투여용량은 하기 표 3에 도시한 바와 같으며, 0.5% 트윈 20(Tween 20)을 음성대조군으로 하였고, 1), 4)에서 수득된 인삼근 농축액 분말 및 인삼잎 추출물과 인삼잎 추출물 가공물의 혼합물을 0.5% 트윈 20에 초음파 분쇄기를 사용하여 용해시켜 각각 양성대조군, 시험군으로 하였다.The dose of each test substance was as shown in Table 3 below, and 0.5
(5) 함량분석(5) Content analysis
상기 제조방법 1)~4)에 대한 분석을 위해 사용된 HPLC는 HITACHI(펌프; L-7100, 검출기; L-7455, 인터페이스; D-7000, 컬럼 오븐; L-7300, 자동시료기; L-7200) 시스템을 사용하였고, 분석조건은 정지상으로 Capcell PAK C18(5㎛), 3.0*75mm를 사용하고 이동상 조건은 A 용매(아세토니트릴), B 용매(물)로 gradient 조건이며, 유속은 0.5mL/min으로 총 분석시간은 110분이며, 컬럼 오븐의 온도는 40℃로 설정하고, 시료의 주입량은 10㎕로 하여, UV 검출기로 203nm에서 검출하였다. 진세노사이드 Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1은 60분 내에 분리되었고, Rg2, Rg3, Rg5, Rk1은 70분 이후에 분리되었다. 상기 본 발명의 방법에 따라 제조된 가공인삼 동결건조물 분석을 위한 시료로는 메탄올로 제조하였다. 진세노사이드 표준 시료는 0.2mg/ml 농도로 준비하였다. 분석 결과를 하기 표 4에 나타내었다. The HPLC used for the above-described methods 1) to 4) was a HITACHI (pump: L-7100, detector: L-7455, interface: D-7000, column oven: L- (Acetonitrile) and B solvent (water), and the flow rate was 0.5 mL (0.5 mL), and the flow rate was 0.5 mL / min, the total analysis time was 110 minutes, the temperature of the column oven was set at 40 ° C, the amount of the sample was set at 10 μl, and the sample was detected with a UV detector at 203 nm. The ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re and Rg1 were isolated in 60 minutes and Rg2, Rg3, Rg5 and Rk1 were separated after 70 minutes. The sample for analysis of the ginseng freeze-dried product prepared according to the method of the present invention was prepared from methanol. A ginsenoside standard sample was prepared at a concentration of 0.2 mg / ml. The results of the analysis are shown in Table 4 below.
(6) 투여(6) Administration
군 분리 다음날부터 운동군은 8주간, 비운동군은 9주간 시험물질을 1일 1회, 존데(zonde)를 사용하여 위내로 경구투여하였다.From the next day, the test substance was orally administered to the stomach using zonde once a day for 8 weeks in the exercise group and 9 weeks in the non-exercise group.
(7) 비운동군과 운동군(7) Non-army forces and exercise groups
음성대조군(용매, 0.5% Tween 20), 양성대조군(UG0714) 및 시험군 (UG0712, 인삼잎 추출물과 인삼잎 추출물 가공물의 혼합물)을 래트에 투여 후 야기되는 운동수행능력 증진효과, 운동 후 피로개선 효과 및 항산화효과를 평가하기 위하여 래트에 각각의 시험물질을 운동군은 8주간 경구투여하고, 런닝머신에서 운동에 대한 적응력을 높여가며 투여 시작 후 2주와 8주에 최대주행거리를 측정하였다. 한편 비운동군은 9주간 경구투여와 함께 6주와 9주 최대주행거리 측정 전 5일 동안의 적응운동 후 운동수행능력 효과를 분석하였다.The effect of increasing the exercise performance after the administration of the negative control (solvent, 0.5% Tween 20), the positive control (UG0714) and the test group (UG0712, a mixture of ginseng leaf extract and ginseng leaf extract) To evaluate the effects and antioxidant effects, each test substance was orally administered to the rats for 8 weeks in the exercise group, and the maximum travel distance was measured at 2 weeks and 8 weeks after the start of the administration, in order to increase the adaptability to exercise in the treadmill. On the other hand, non - exercise group analyzed the effect of exercise performance after adaptive exercise for 5 days before the 6 - week and 9 - week maximum distance measurement with oral administration for 9 weeks.
(8) 일반증상 관찰 및 체중 측정(8) General symptom observation and weight measurement
일반증상은 시험물질 투여기간 중 1일 1회 매일 관찰하며 관찰기간 중 1일 1회 사망개체 발생여부를 확인하였다. 시험에 사용된 시험동물의 체중은 예비군 분리 시, 시험물질투여직전, 시험물질 투여 개시 후 주 1회 및 부검 직전에 측정하였다.The general symptoms were observed daily once daily during the test substance administration period and the occurrence of deaths was confirmed once a day during the observation period. The body weights of the test animals used in the test were measured immediately prior to the test substance administration, once a week after the start of the test substance administration, and immediately before the autopsy.
(9) 부검 시 혈액 샘플 및 분석샘플 채취(9) Blood sample and analysis sample collection at autopsy
부검 시 복강을 열고 복대정맥을 통해 전혈 채혈 후 항피로마커 분석용, 혈중 젖산, 코르티코스테로이드 분석용으로 각각 전용 용기에 담아 4시간 이내에 분석하였다. 근육샘플은 근육의 손상을 최소화하기 위해 이소펜탄으로 완충시킨 후 액화질소로 동결시켰다. 동결시킨 근육샘플은 동결 건조기(deep freezer)에 보관하였다.During the autopsy, the abdominal cavity was opened, whole blood was collected through the abdominal vein, analyzed for anti-fatigue markers, blood lactate, and corticosteroid for 4 hours. Muscle samples were buffered with isopentane and frozen with liquefied nitrogen to minimize muscle damage. The frozen muscle samples were stored in a deep freezer.
실시예 1: 인삼잎 추출물과 인삼잎 추출물 가공물의 혼합물의 운동능력 증진 효과 Example 1 Effect of Ginseng Leaf Extract and Ginseng Leaf Extract Composition on Exercise Capacity
(1) 실험과정(1) Experimental process
1) 시험물질의 투여1) Administration of test substance
런닝머신(treadmill)을 통해 운동효과를 측정하여 시험물질의 에너지 부스팅 효과를 평가하였으며, 래트에 시험물질 즉, 음성 대조군 (0.5% 트윈 20 용매), UG0714 (인삼근 추출물, 양성 대조군) 및 UG0712(인삼잎 추출물 분말 및 인삼잎 추출물 가공물의 혼합물, 시험군)을 경구투여하였다.(0.5
2) 측정방법2) Measurement method
A. 일반증상 관찰: 일반증상은 시험물질 투여기간 중 1일 1 회 매일 관찰하며 관찰기간 중 1일 1 회 사망 개체 발생 여부를 확인하였다. A. General Symptom Observations: The general symptoms were observed daily once daily during the test substance administration period, and the occurrence of deaths was confirmed once a day during the observation period.
B. 체중 측정: 시험에 사용된 시험동물의 체중은 예비 군 분리시, 시험물질 투여 직전, 시험물질 투여 개시 후 주 1 회 체중을 측정하였다. B. Body weight measurement: The body weight of the test animals used in the test was measured at the time of separation of the reserve group, immediately before administration of the test substance, and once a week after the start of administration of the test substance.
C. 비운동군 훈련 및 최대운동량 측정: 비운동군의 동물 10마리는 9주간 시험물질은 투여하며 6주와 9주에 최대운동량을 측정하였다. 최대운동량 측정시에는 런닝머신에서 4일 동안 기울기(0%~15%), 속도(20~40cm/sec)와 활동주기(10~20분)으로 증가시키면서 훈련 5일째 최대주행시간을 측정하였다. 측정된 개체 10마리 중 하위 2마리를 제거하고, 상위 8마리의 결과 값을 이용하였다. C. Non-exercise group training and maximal momentum measurement: Ten animals in the non-exercise group were given the test substance for 9 weeks and the maximum exercise was measured at 6 and 9 weeks. The maximum exercise time was measured on the 5th day of training with increasing the slope (0% ~ 15%), the speed (20 ~ 40cm / sec) and the activity period (10 ~ 20min) for 4 days on the running machine. The lower 2 out of 10 animals were removed and the results from the upper 8 were used.
D. 운동군 훈련 및 최대 운동량 측정: 운동군의 동물 9마리는 런닝머신에서 운동시켰다. 4주 동안 운동은 기울기(0%~15%), 속도(20~30cm/sec)와 활동주기(30~40분)으로, 나머지 4주 동안은 기울기 15%, 속도 (30~40cm/sec), 활동주기(30~40분)으로 증가시키면서 수행하였다. 동물은 2일 운동하고 2일 동안 쉬는 2일 주기로, 계속해서 운동시켰다. 훈련기간의 2주와 8주째에 최대주행시간을 운동군에서 측정하며, 측정된 개체 9마리 중 하위 2마리의 측정값을 제거하고, 상위 7마리의 측정값을 결과에 이용하였다. D. Exercise Training and Maximum Momentum Measurement: Nine animals in the exercise group were exercised on a treadmill. At 4 weeks, the slope was 15%, the speed (30 ~ 40cm / sec), the slope (0 ~ 15%) and the speed (20 ~ 30cm / , And activity cycle (30-40 minutes). The animals continued to exercise for 2 days and 2 days for 2 days. At the 2nd and 8th weeks of training, the maximal driving time was measured in the exercise group, the lower 2 measurements of the 9 animals were removed, and the upper 7 measurements were used for the results.
(2) 결과(2) Results
5% 기울기, 30cm/sec, 전기자극 유도 90분에 따른 운동군 2주 후의 래트의 최대 주행거리 측정 결과, 도 1에서 보는 바와 같이 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물(UG0712)을 투여한 래트의 운동능력은 음성 대조군의 것보다 유의성 있게 증가하였다 (p<0.00001). 또한, UG0712의 운동능력은 인삼근 농축액 분말(UG0714)을 투여한 래트의 것보다 유의성 있게 증가하였다 (p<0.05). As shown in FIG. 1, the maximum range of the rats after 2 weeks of the exercise group according to the slope of 5%, 30 cm / sec, and the induction of electrical stimulation for 90 minutes was as shown in FIG. 1, in which the mixture of the ginseng leaf extract and the ginseng leaf extract composition (UG0712) The athletic performance of the rats was significantly higher than that of the negative control group (p <0.00001). In addition, the athletic performance of UG0712 was significantly increased (p <0.05) than that of the rat administered with the ginseng muscle concentrate powder (UG0714).
15% 기울기, 35cm/sec, 전기자극 유도 90분에 따른 운동군 8주 후의 래트의 최대 주행거리 측정 결과, 도 2에서 보는 바와 같이 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물(UG0712)을 투여한 래트의 운동능력은 음성 대조군의 것보다 유의성 있게 증가하였다 (p<0.01). 또한, UG0712를 투여한 경우 운동능력은 인삼근 농축액 분말(UG0714)을 투여한 래트보다 유의성 있게 증가하였다 (p<0.005). As shown in FIG. 2, the maximum distance traveled by the rats after 8 weeks of the exercise group according to the slope of 15%, 35 cm / sec, and the electric stimulation induction time of 90 minutes showed that the mixture of the ginseng leaf extract and the ginseng leaf extract composition (UG0712) The athletic ability of the rats was significantly increased (p < 0.01) than that of the negative control group. In addition, when UG0712 was administered, the athletic ability was significantly increased (p <0.005) compared with the rats administered with the ginseng muscle concentrate powder (UG0714).
5% 기울기, 35cm/sec, 전기자극 유도 90분에 따른 비운동군 6주 후의 래트의 최대 주행거리 측정 결과, 도 3에서 보는 바와 같이 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물(UG0712)을 투여한 래트의 운동능력은 음성 대조군의 것보다 유의성 있게 증가하였다 (p<0.05). 또한, UG0712를 투여한 경우 운동능력은 인삼근 농축액 분말(UG0714)을 투여한 래트보다 유의성 있게 증가하였다 (p<0.05). As shown in FIG. 3, the maximum distance traveled by the rat after 6 weeks of the non-raising group at 5% slope, 35 cm / sec and electrical stimulation induced 90 minutes showed that the mixture of the ginseng leaf extract and the ginseng leaf extract composition (UG0712) The athletic performance of the rats was significantly increased (p < 0.05) than that of the negative control group. In addition, when UG0712 was administered, the athletic ability was significantly increased (p <0.05) as compared with the rats administered with the ginseng muscle concentrate powder (UG0714).
10% 기울기, 35cm/sec, 전기자극 유도 90분에 따른 비운동군 9주 후의 래트의 최대 주행거리 측정 결과, 도 4에서 보는 바와 같이 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물(UG0712)을 투여한 래트의 운동능력은 음성 대조군의 것보다 유의성 있게 증가하였다 (p<0.001). 또한, UG0712를 투여한 경우 운동능력은 인삼근 농축액 분말(UG0714)을 투여한 래트보다 유의성 있게 증가하였다 (p<0.05). As shown in FIG. 4, the maximum distance of travel of the rat after 9 weeks of non-raising group at 10% slope, 35 cm / sec, and electrical stimulation induced 90 minutes showed that the mixture of ginseng leaf extract and ginseng leaf extract (UG0712) The athletic performance of the rats was significantly higher than that of the negative control group (p < 0.001). In addition, when UG0712 was administered, the athletic ability was significantly increased (p <0.05) as compared with the rats administered with the ginseng muscle concentrate powder (UG0714).
따라서, 본 발명의 인삼잎 추출물 및 인삼잎 추출물 가공물의 혼합물은 동물의 운동능력을 효율적으로 증진시킨다는 것을 알 수 있으며, 인삼근 추출물 또는 음성대조군 보다 그 효능이 우수함을 알 수 있다.Therefore, it can be seen that the mixture of the ginseng leaf extract and the ginseng leaf extract composition of the present invention effectively promotes the exercise capacity of the animal, and it is more effective than the ginseng root extract or the negative control.
실시예Example 2. 2. 항피로마커Anti-fatigue marker 측정 Measure
장기간의 운동 및 탈진적 최대주행거리 측정에 의한 운동 스트레스에 대한 시험물질의 항스트레스 효과를 검색하기 위해 비운동군과 운동군 모두에서 최대운동거리 측정 전후 혈중 항피로 마커를 측정하였다. 이를 위해 최대 운동시험 1일전과 운동 후 20분 이내에 혈액을 경정맥 채혈하여 혈청을 분리하였다. 크레아틴 킨아제(Creatine kinase, CK) 및 LDH(lactate dehydrogenase)를 혈액생화학분석기(Hitachi 7080, 일본)를 사용하여 측정하였다. 혐기성 산화능과 관련되는 LDH는 37℃에서 분광광도계 (spectrophotometer)로 흡광도를 측정하였으며, 모든 측정치는 Umol/min/g로 표시하였다. The anti - fatigue markers were measured before and after the measurement of the maximum exercise distance in both non - exercise group and exercise group in order to search for the antistress effect of the test substance on the exercise stress by long - term exercise and exhaust maximal travel distance measurement. For this purpose, blood was collected from the jugular vein within one day before the maximal exercise test and within 20 minutes after the exercise to separate the serum. Creatine kinase (CK) and lactate dehydrogenase (LDH) were measured using a blood biochemical analyzer (Hitachi 7080, Japan). LDH, which is related to anaerobic oxidizing ability, was measured by a spectrophotometer at 37 ° C, and all measured values were expressed in Umol / min / g.
젖산 및 코르티코스테로이드(AssayMax Corticosterone ELISA Kit, Gentaur, catalog No. EC3001-1)는 운동군의 경우 8주 최대주행거리 측정 후 혈액을, 비운동군의 경우 9주 최대주행거리 측정 후 얻은 혈액에서 분석하였다. 측정결과는 하기 표 5 내지 표 12에 나타난 바와 같다.Lactic acid and corticosteroids (AssayMax Corticosterone ELISA Kit, Gentaur, catalog No. EC3001-1) were analyzed in the blood obtained after 8 weeks of maximum distance measurement in the exercise group and in the blood obtained after 9 weeks of maximum distance measurement in the non-exercise group . The measurement results are shown in Tables 5 to 12 below.
CK (creatine kinase)는 다양한 조직에서 발현되는 효소의 하나로 ATP를 소비하여 크레아틴을 크레아틴 인산 및 ADP로 변환시키는 데 관여하며, 임상적으로 혈중 CK는 심근경색(myocardial infarction), 횡문근 융해(rhabdomyolysis, severe muscle breakdown), 근육퇴행위축 (muscular dystrophy) 및 급성 신부전(acute renal failure)에 있어서 마커로 사용될 수 있다. 근육이 손상되면 혈중 CK 레벨이 증가하게 된다.CK (creatine kinase) is one of the enzymes expressed in various tissues and is involved in the conversion of creatine into creatine phosphate and ADP by consuming ATP. Clinically, blood CK is myocardial infarction, rhabdomyolysis, severe muscle breakdown, muscular dystrophy, and acute renal failure. When the muscle is damaged, the blood CK level is increased.
실험결과 UG0712를 투여한 경우, CK 레벨이 현저히 감소하였으며(도 5), 이를 통해 UG0712 투여시 운동으로 인한 근손상 등을 효과적으로 억제할 수 있음을 알 수 있다.Experimental results showed that CK levels were significantly decreased when UG0712 was administered (FIG. 5), and it was found that UG0712 effectively inhibited muscle damage due to exercise.
LDH는 해당 효소 피루베이트(glycolytic enzyme pyruvate)와 젖산(lactate) 사이의 촉매작용에 반영되는 세포질에 존재하는 효소이며, 일반적으로 운동 후의 피로는 근육이 오랜 기간 강력한 수축을 지속한 결과 근세포내로 산소가 불충분하게 공급되면서 근육활동에 필요한 에너지를 혐기에너지 시스템(anaerobic energy system) 경로를 통해 생성하게 됨으로써 근육에 많은 젖산이 축적되어 발생하는데, LDH는 해당과정의 좋은 마커가 된다. LDH is an enzyme present in the cytoplasm that is reflected in the catalytic action between the glycolytic enzyme pyruvate and the lactate. Generally, fatigue after exercise is a long-lasting strong contraction of the muscle, Inadequately supplied, the energy required for muscle activity is generated through the anaerobic energy system pathway, resulting in the accumulation of many lactic acid in the muscle, which is a good marker for the process.
UG0712를 비운동군에 투여한 경우, 혈중 LDH 활성은 음성대조군 및 양성대조군에 비해 통계학적으로 유의하게 감소하였으며 (도 6), 운동군에 투여한 경우 음성대조군 및 양성대조군에 비해 혈중 및 근육 중 LDH의 농도가 현저하게 감소하였다 (도 7 및 8).When UG0712 was administered to the non-emptied group, serum LDH activity was significantly lower than that of the negative control group and the positive control group (FIG. 6). When administered to the exercise group, the LDH activity in blood and muscle (Figs. 7 and 8).
실험결과 운동군의 경우 비운동군에 비하여 LDH가 전체적으로 증가하는 경향이 나타났으며, 이는 정기적인 운동에 의해 근육에 가해지는 부하증가로 LDH 효소 활성도가 증가한 때문인 것으로 보인다. Experimental results showed that LDH increased overall in the exercise group compared with non-exercise group. This is due to the increase in the LDH enzyme activity due to the increase in the load applied to the muscle by the regular exercise.
운동군의 LDH 활성은 UG0712 투여시 현저히 감소하였는데, 이를 통해 UG0712의 투여를 통해 근육에서의 젖산 생성이 억제되고 피로도가 감소하여 런닝머신에서의 운동능력 향상에 도움이 될 것으로 보인다.The LDH activity in the exercise group was significantly decreased when UG0712 was administered. This suggests that administration of UG0712 would inhibit lactic acid production in the muscle and reduce fatigue, thereby improving exercise performance in the running machine.
운동강도 및 지속시간과 밀접한 관련이 있는 주요 피로인자 중 하나로 알려진 젖산은 피루베이트(pyruvate)가 환원되어 생성된 혐기성 해당반응의 종말대사체로서 강력한 운동 스트레스에 의해 혈중 농도가 증가하게 되며, 젖산이 축적되면 체내 산성화가 초래되어 여러 글루코즈 신생에 관계하는 요인들을 억제하게 된다. Lactic acid, known as one of the major fatigue factors closely related to exercise intensity and duration, is an endogenous metabolite of an anaerobic reaction produced by the reduction of pyruvate, resulting in an increase in blood concentration due to strong exercise stress. Accumulation leads to acidification of the body and inhibits factors related to multiple glucose neogenesis.
실험 결과를 살펴보면, 비운동군 및 운동군에 UG0712를 투여한 경우, 음성대조군에 비해 혈중 젖산이 유의성 있게 감소하였으며 (도 9 및 10), 따라서 UG0712를 투여하는 경우 운동시 발생하는 피로인자를 줄임으로써 운동능력을 증진시킬 수 있음을 알 수 있다.The results of the experiment showed that when UG0712 was administered to the non-exercise group and the exercise group, blood lactate was significantly lower than that of the negative control group (FIGS. 9 and 10), and therefore, when UG0712 was administered, It is possible to improve exercise ability.
대표적인 스트레스 인자로 알려진 코르티코스테로이드(corticosteroids)는 운동 중 해당과정에 중요한 역할을 담당하며, 운동강도에 따라 혈중 레벨이 달라진다. 지구성 운동과 고강도 운동 모두에서 증가양상을 보이며, 카테콜아민(catecholamine)과는 달리 운동 후 즉시 감소하지 않고 일정 시간동안 증가된 수준을 유지한다. 장기간 코르티코스테로이드가 고농도로 유지되면 체내 단백질이 분해되거나 손상되며, 질소 균형을 저해하는 부작용이 야기될 수 있다. 실험 결과를 살펴 보면, 비운동군 및 운동군에 UG0712를 투여한 경우 음성대조군 에 비해 혈중 코르티코스테론이 현저히 감소하였다 (도 11 및 12). 따라서, UG0712의 투여를 통해 스트레스 인자의 농도를 낮춤으로써 운동능력을 더욱 증진시킬 수 있음을 알 수 있다.Corticosteroids, known as typical stressors, play an important role in the process during exercise, and their blood levels vary with exercise intensity. In both endurance exercise and high intensity exercise, it shows an increase pattern. Unlike catecholamine, it does not decrease immediately after exercise but maintains the increased level for a certain time. If long term corticosteroids are maintained at high concentrations, body proteins may be degraded or damaged, and side effects may be caused by inhibiting nitrogen balance. The results of the experiment showed that the administration of UG0712 to the non-exercise group and the exercise group significantly reduced the blood corticosterone level compared to the negative control group (FIGS. 11 and 12). Thus, it can be seen that lowering the concentration of stress factors through the administration of UG0712 can further enhance exercise capacity.
실시예Example 3. 운동능력 향상효과 측정 3. Measurement of exercise capacity improvement effect
일반적으로 운동과 관련하여 근육대사는 산화력을 증가시키고 근육피로 상태를 지연시키는 쪽으로 변화를 겪으며, 이러한 변화는 근육내 미토-산화성 효소(mito-oxidative enzyme)의 활성에 반영되어 운동기간과 강도에 따라 변화가 나타난다. 이러한 미토-산화성 효소로는 시트레이트 합성효소(citrate synthase), 사이토크롬 C 옥시다제(Cytochrome C oxidase), 숙시네이트 디하이드로제나제(succinate dehydrogenase) 등이 있으며, 특히 시트레이트 합성효소는 호기성 산화능의 좋은 마커로 잘 알려져 있다. 이 중 비운동군과 운동군 모두에서 운동능력 향상에 관련성이 있는 생화학적 지표를 검색하기 위해 근육을 취해 호기성 산화능과 관련된 CS(citrate synthase)의 활성도를 측정하였다.In general, in relation to exercise, muscle metabolism changes to increase oxidative capacity and to delay muscle fatigue. This change is reflected in the activity of the mito-oxidative enzyme, Changes appear. Examples of such mitochondria-oxidizing enzymes include citrate synthase, cytochrome C oxidase, succinate dehydrogenase, and the like. Particularly, the citrate synthase has an aerobic oxidizing ability Well known as a good marker. To investigate biochemical markers related to exercise capacity improvement in both non - exercise group and exercise group, muscle activity was measured and the activity of CS (citrate synthase) related to aerobic oxidative capacity was measured.
근육을 50 mL TRIS 중의 2mM MgCl2 및 2mM EDTA 용액 중에 넣고 4℃에서 균일화하였다. 근육에 있어 호기성 산화에 의한 에너지 생성과 관련된 CS(citrate synthase)는 37℃에서 분광광도계(spectrophotometer)로 흡광도를 측정하였으며, 모든 측정치는 Umol/min/g로 표시하였다.Into the muscle 2mM MgCl 2 and 2mM EDTA solution in 50 mL TRIS was homogenized in 4 ℃. Citrate synthase (CS), which is involved in energy production by aerobic oxidation in muscles, was measured by spectrophotometer at 37 ° C. All measurements were expressed in terms of Umol / min / g.
CS 활성도 분석결과, UG0712를 비운동군 및 운동군에 투여한 결과 CS 활성도가 현저히 증가하는 것으로 나타났다 (도 13 및 14). 이와 같이, UG0712 투여시 호기성 산화에 의한 에너지 생성과 관련된 CS 활성도가 증가함으로써 운동 수행에 있어 산소의 최대 소비량이 증진되고, 운동수행능력에 도움을 줌으로써 런닝머신에서의 최대주행거리가 시험군의 경우 운동대조군이나 양성대조군에 비하여 높은 것으로 보인다. CS activity analysis showed that CS activity was significantly increased when UG0712 was administered to untreated and exercise groups (Figures 13 and 14). In this way, when the UG0712 administration is performed, the maximum activity of oxygen in the exercise performance is increased and the exercise performance is improved by increasing the activity of the enzyme related to energy generation by aerobic oxidation, Compared with the exercise control group and the positive control group.
실시예Example 4. 항산화효과 측정 4. Antioxidant effect measurement
산소 자유 라디컬 (oxygen free radical) 및 활성산소종(ROS, reactive oxygen species)은 인체 대사과정 뿐만 아니라 격렬한 운동시 생성되어 단백질 및 DNA를 변형시켜 생체막을 손상시킴으로써 결국 생체 조직 자체에 악영향을 미치며, 더 나아가 암과 성인병의 원인이 된다고 보고된 바 있다. 세포내에 존재하는 미토콘드리아, 퍼옥시좀, 잔틴 옥시다제(xanthine oxidase), NADPH 옥시다제 및 COX(cyclooxygenase) 등의 효소들은 여러 활성산소종(ROS)을 생성하는데, 이러한 ROS는 산화손상을 야기하며, 또한 활성질소종은 염증반응에서도 다량으로 생성되고, 이때 활성산소종도 함께 생성된다. 장기간의 운동과 과도한 운동에 의한 근육내 염증반응이 일어나게 되면 NO와 같은 염증인자들이 만들어지게 된다.Oxygen free radicals and reactive oxygen species (ROS) are generated not only in human metabolic processes but also in vigorous exercise, damaging biological membranes by modifying proteins and DNA, It has been reported that it causes cancer and adult diseases. Enzymes such as mitochondria, peroxisome, xanthine oxidase, NADPH oxidase and COX (cyclooxygenase) present in cells produce various reactive oxygen species (ROS), which cause oxidative damage, In addition, active nitrogen species are produced in large quantities in the inflammatory reaction, and active oxygen species are also produced at the same time. Long-term exercise and excessive muscle-induced inflammatory responses to exercise will produce inflammatory factors such as NO.
이렇게 만들어진 과도한 프리라디컬의 제거를 위한 항산화 체계는 1차적으로는 SOD, GPx(glutathione peroxidase) 등의 항산화효소 및 항산화비타민, 글루타티온과 같은 내인성 비효소계 항산화제가 있으며, 2차적으로 손상된 DNA 세포내 구성성분을 원상회복시키는 DNA 리페어 효소(DNA repair enzyme)가 있다.The antioxidant system for the elimination of excess free radicals is composed of antioxidant enzymes such as SOD and GPx (glutathione peroxidase), endogenous non-enzymatic antioxidants such as antioxidant vitamins and glutathione, There is a DNA repair enzyme that recovers the ingredients.
항산화효과를 평가하기 위하여 혈중과 근육에서 NO 분석을, 뒷다리 근육에서 SOD, GPx 효소 활성도를 분석하였다.In order to evaluate the antioxidant effect, NO analysis was performed in blood and muscle, and SOD and GPx enzyme activities in hindlimb muscle were analyzed.
근육 내 SOD (superoxide dismutase) 저해율은 상용화된 SOD kit (superoxide dismutase Assays Designs, Catalog No. 30-023)을 사용하여 측정하였다.The intramuscular SOD (superoxide dismutase) inhibition rate was measured using a commercial SOD kit (superoxide dismutase Assays Designs, Catalog No. 30-023).
근육내 GPx(glutathione peroxidase) 활성은 NADPH의 변화(감소)를 측정하여 GPx를 분석하는 Glutathione Peroxidase Activity kit (Assays Designs Cat. No. 900-158)를 이용하여 분석하였으며, 그 활성도를 계산하기 위해 하기 계산식을 사용하였다.The activity of glutathione peroxidase (GPx) in muscle was analyzed using Glutathione Peroxidase Activity Kit (Assays Designs Cat. No. 900-158), which measures the change (decrease) of NADPH and analyzes GPx. The equation was used.
산화질소(NO, Nitric oxide)는 산화질소 합성효소(NOS, nitric oxide synthase)의 촉매작용에 의해 아르기닌으로부터 합성되며, 골격근 혈류량은 NOS 억제제에 의해 억제되고, 운동시 골격근 혈류량의 증가는 NO 증가를 암시한다고 알려져 있다. 따라서 혈중 및 근육내 NO의 양은 근육 내 여러 산화적 스트레스 요인의 간접적인 지표로 예측이 가능하다. Nitric oxide (NO) is synthesized from arginine by the catalytic action of nitric oxide synthase (NOS), skeletal muscle blood flow is inhibited by NOS inhibitors, and increased skeletal muscle blood flow during exercise increases NO It is known to suggest. Therefore, the amount of NO in the blood and muscle can be predicted as an indirect indicator of various oxidative stress factors in the muscle.
시험물질 투여 8주 후 운동군의 NO 분석결과를 보면 혈중에서는 운동대조군에 비해 비운동군에서 전체적으로 낮은 경향을 보였다. 비운동 시험물질 UG0712군은 62±15.36 micromol/mL로 운동대조군에 비해 유의성 있는 감소가 나타났다. 근육에서의 결과를 보면, 혈중 결과와 동일하게 비운동군에 비해 운동군의 수치가 높게 나타났고 유의한 차이를 나타냈다. 비운동군 결과에서 비운동 UG0712군에서 5±0.44 micromol/mL로 비운동대조군(p<0.05), 운동대조군 (p<0.01)과 유의성 있는 감소 경향이 나타났다 (도 15 내지 도 19). 이를 통해 UG0712의 투여로 인하여 산화적 스트레스 요인이 감소함을 알 수 있다.After 8 weeks of the test substance administration, the results of the NO analysis of the exercise group showed a lower tendency in the blood compared with the exercise control group as a whole. The non-exercise test substance UG0712 group showed a significant decrease of 62 ± 15.36 micromol / mL compared to the exercise control group. The results in the muscles showed that the exercise group had higher values than the non - exercise group and the difference was significant as the blood results. The non-exercise group showed a significant decrease of 5 ± 0.44 micromol / mL in the non-exercise UG0712 group compared to the non-exercise control group (p <0.05) and the exercise control group (p <0.01) (FIGS. 15 to 19). This suggests that the administration of UG0712 reduces oxidative stressors.
SOD(superoxide dismutase)는 유산소운동과정의 첫 번째 생성물인 수퍼-옥사이드 라디칼을 과산화수소와 산소분자로 만드는 항산화 효소 시스템 중에서 가장 중요한 효소 중의 하나로, 산화적 스트레스에 의한 지표로 많이 사용되는 항산화효소이다. 즉 SOD는 산화질소와 수퍼옥사이드(O2-)가 반응해 생기는 강력한 산화물질인 퍼옥시니트레이트(peroxynitrate)의 형성을 미연에 방지하는 역할을 수행하게 되며, 규칙적인 운동은 SOD 활성을 증가시킨다고 보고되어 있으므로, SOD 산화억제율 측정을 통해 항산화효과를 확인할 수 있다. SOD (superoxide dismutase) is one of the most important enzymes in the antioxidant enzyme system that makes superoxide radicals, the first product of the aerobic exercise process, into hydrogen peroxide and oxygen molecules. It is an antioxidant enzyme that is often used as an index by oxidative stress. That is, SOD prevents the formation of peroxynitrate, which is a strong oxidizing substance caused by reaction of nitrogen oxide and superoxide (O 2- ), and regular exercise increases SOD activity Therefore, the antioxidative effect can be confirmed by measuring SOD oxidation inhibition rate.
실험 결과, UG0712 투여군의 경우 운동군에서 근육 중 SOD 산화억제율(%)이 증가하는 것으로 나타났다 (도 20). 따라서, UG0712를 투여함으로써 산화적 스트레스에 의해 생성되는 산화물질의 생성을 효과적으로 억제할 수 있음을 알 수 있다.As a result, in the UG0712-treated group, the SOD oxidation inhibition rate (%) in muscle was increased in the exercise group (Fig. 20). Therefore, it can be seen that administration of UG0712 effectively inhibits the production of oxidized products produced by oxidative stress.
GPx(glutathione peroxidase)는 산화적 손상으로부터 장기를 보호하는 효능을 갖는 항산화효소의 하나이며, 근육 내 GPx의 활성을 분석함으로써 항산화효능의 측정이 가능하다.GPx (glutathione peroxidase) is an antioxidant enzyme that protects organs from oxidative damage. Antioxidant activity can be measured by analyzing the activity of intramuscular GPx.
실험결과, UG0712 투여군의 경우 운동군에서 음성대조군에 비해 근육 중 GPx가 증가하는 것으로 나타났다 (도 21). 따라서, UG0712를 투여하는 경우 운동으로 인한 산화적 손상으로부터 장기를 효과적으로 보호할 수 있음을 알 수 있다.Experimental results showed that UG0712-treated group had an increase in muscle GPx in the exercise group compared to the negative control group (Fig. 21). Therefore, it can be seen that administration of UG0712 effectively protects organs from oxidative damage due to exercise.
실시예Example 4. 4. ATPaseATPase 테스트 Test
에너지 이용에 관련된 뒷다리 근육별 근섬유의 변화를 관찰하기 위해 미오신 ATPase(myosin ATPase)에 대한 조직화학 염색을 실시하여 운동수행능력에 관한 보조적인 지표로 사용하였다. In order to observe changes in muscle fiber of the hind leg muscles related to energy utilization, histochemical staining of myosin ATPase (myosin ATPase) was performed and used as an auxiliary index of exercise performance.
1) 실험방법1) Experimental method
왼쪽 뒷다리 근육을 20℃에서 12㎛로 마이크로톰(microtome)을 이용해 냉동절삭 하였다. 냉동절삭 후, 헴토실린-에오신(Hemtoxylin-eosin)으로 신속히 염색하여 섬유소의 이행 상태를 확인하면서 연속절편을 각 블록으로부터 얻어 현미경 슬라이드에 고정시켰다. 산 전배양(acid preincubation)시켜서 미오신 ATPase 염색을 시행하였다. 근육마다 최소 200개의 섬유들을 각 동물마다 계산하였다.The left hindlimb muscle was frozen at 20 째 C to 12 쨉 m using a microtome. After cryo-cutting, serial sections were obtained from each block and fixed on a microscope slide, while rapidly staining with Hemtoxylin-eosin to confirm the progress of the fibrin. Myocyte ATPase staining was performed by acid preincubation. At least 200 fibers per muscle were calculated for each animal.
2) 결과2) Results
운동에 관계되는 근육은 미오신 ATPase 염색을 통해 크게 type Ⅰ 및 type Ⅱ 섬유로 나누어진다. The muscles involved in exercise are divided into type I and type II fibers through myosin ATPase staining.
Type Ⅰ 섬유는 에너지원으로 글루코즈 및 지방을 호기적으로 이용하는 유산소에너지 대사를 함으로써 피로에 강하고 수축속도가 느려 장시간의 지구성운동에 적합한 근육으로 통상 레드 근육(red muscle)을 일컫는다. Type Ⅰ fiber is an energy source that uses glucose and fat to aerobically metabolize aerobic energy, which is resistant to fatigue and slows the rate of contraction, and is suitable for long-term endurance exercise. It usually refers to red muscle.
Type Ⅱ 섬유는 혐기적 무산소 에너지 대사를 함으로써 피로에 약하고 수축속도가 빨라 단시간의 단거리 운동에 적합한 근육으로 통상 화이트 근육(white muscle)이라 한다. Type Ⅱ fibers are anaerobic anaerobic energy metabolism, weak fatigue and rapid shrinking speed, so it is suitable for short-term short-term exercise, usually white muscle (white muscle) is called.
운동에 관계하는 주요 뒷다리 근육에서의 type I 섬유(fibers)와 type II 섬유의 변화를 관찰하기 위한 근육별(soleus, red gastro.) 미오신 ATPase 조직화학 염색 결과에서는 전체적으로 시험물질 투여 운동군의 산화 섬유 type I 섬유(oxidative fibers type I fibers) 비율이 비운동군의 비율보다 높게 나타났다. 가자미근(soleus)에서는 운동군 시험물질 UG0712군의 type I 섬유 비율이 비운동 대조군에 비해 유의성 있는 증가(UG0712; P < 0.01)가 나타났다. 운동군 UG0712군은 운동대조군에 비해 레드 장딴지근(red gastrocnemius) type I 섬유 비율의 유의성 있는 증가(P < 0.05.)가 나타났다 (도 22 및 도 23). The results of histochemical staining for myosin ATPase muscle (soleus, red gastro) to observe the changes of type I fibers and type II fibers in the main hindlimb muscles related to exercise are shown in Fig. The ratio of type I fibers (oxidative fibers type I fibers) was higher than that of non - In soleus, the type I fiber ratio of exercise group test substance UG0712 group showed a significant increase (UG0712; P <0.01) compared to the non-exercise control group. The exercise group UG0712 showed a significant increase (P <0.05) in the ratio of red gastrocnemius type I fibers (FIG. 22 and FIG. 23) compared to the exercise control group.
또한, 8주 동안 운동과 함께 시험물질을 투여한 운동군에서 type I 섬유가 전체적으로 비운동군에 비해 약간 증가하였는데, 이는 지속적인 운동에 대한 보상작용으로 근섬유 조성이 type I 섬유가 증가하였기 때문으로 보인다. In addition, type I fibers were slightly increased in the exercise group treated with exercise for 8 weeks compared to the non-exercised group. This seems to be due to the increase in type I fibers in the muscle fiber composition due to the continuous action.
따라서 UG0712투여시, 전체적으로 운동군의 산화 섬유 type I 섬유(oxidative fibers typeⅠfibers) 비율이 비운동군의 비율보다 높게 나타난 이유는 지속적인 운동에 의해 근육의 대사체계가 산화력을 증가시키고 근육피로 상태를 지연시키는 방향으로 이루어지는 것으로 여겨진다. 또한, 이러한 현상은 시험물질인 UG0712 투여에 의해 더욱 증가되어 런닝머신에서의 운동수행능력이 증가된 것으로 사료된다. Therefore, when UG0712 was administered, the proportion of oxidative fibers type I fibers in the exercise group was higher than that in the non-exercise group, because the metabolic system of muscles increased the oxidative power and the muscle fatigue state was delayed . ≪ / RTI > In addition, this phenomenon is further increased by administration of UG0712, which is a test substance, and it is considered that the exercise performance in running machine is increased.
실시예 5. 인체에서 운동능력 개선 효과 평가 ( VO 2 max 및 AT 측정) 및 안전성 테스트 Example 5: Evaluation of exercise capacity improvement effect in human body ( VO 2 max and AT measurements) and safety testing
(1) 시험방법(1) Test method
단일기관(single center), 이중맹검 (double-blind), 무작위배정(random allocation) 및 위약대조(placebo control)방법을 사용하였다. Single center, double-blind, random allocation, and placebo control methods were used.
만20세 이상인 건강한 자로써, 시험 참여 3개월내에 정기적으로 운동을 하지 않은 자를 피험자로 선정하였다. 총 모집 피험자 수는 123명이었으나, 완료 피험자수는 82명이었다. 피험자를 UG0712 고용량군, UG0712 저용량군 및 대조군의 각 군에 무작위 배정하였고, 시험은 이중맹검으로 실시하였다. Subjects who were healthy and over 20 years old and who did not exercise regularly within 3 months of the trial were selected as subjects. The total number of subjects was 123, but the number of completed subjects was 82. Subjects were randomly assigned to each of the UG0712 high dose group, the UG0712 low dose group, and the control group, and the test was conducted in a double-blind manner.
UG0712 고용량군은 1일 2회, 1회 250 mg으로 총 500 mg 용량을 섭취하고, UG0712 저용량군은 1일 2회, 1회 50 mg으로 총 100 mg 용량을 섭취하였다. 대조군(위약군)은 CMC(carboxymethylcellulose)를 1일 2회, 1회 250 mg으로 총 500 mg 용량을 섭취하였다. The UG0712 high-dose group received a total dose of 500 mg twice daily, 250 mg once, and the UG0712 low-dose group received a total dose of 100 mg twice a day, once at 50 mg. Control group (placebo group) received CMC (carboxymethylcellulose) twice a day, 250 mg once a total dose of 500 mg.
시험제제 투여기간은 12주이며, 각 피험자는 정해진 운동(주3회, 60~90분간 유산소운동 및 근력운동)을 하였다. 유산소운동은 70 ~ 80% VO2max 강도로 런닝머신(Treadmill)과 에르고미터(ergometer)를 이용하여 진행하였다. 그리고 운동 횟수는 2주에 한 번씩 주기적으로 측정하였다. 주 3회 연구기관에서 정한 스포츠센터를 이용하는 것으로 하였다.The test drug administration period was 12 weeks, and each subject underwent a prescribed exercise (three times a week, aerobic exercise and strength exercise for 60 to 90 minutes). Aerobic exercise was performed using a treadmill and an ergometer with a 70 to 80% VO 2 max intensity. The number of exercises was measured periodically every two weeks. Three times a week, it was decided to use the sports center designated by the research institute.
시험제제를 섭취한 당일, 4, 8, 12주 째 되는 날 VO2 max 및 AT에 대한 평가를 실시하였고, 안전성 테스트를 하였다. VO 2 max and AT were assessed on the day, 4, 8, and 12 weeks after ingestion of the test product, and safety tests were performed.
(2) VO2 max 측정(2) Measurement of VO 2 max
운동능력 개선 효과를 평가하기 위하여 VO2 max를 측정하였다.The VO 2 max were measured in order to evaluate the exercise capacity improvement.
전체 피험자군에 대한 VO2 max (최대산소섭취량) 분석결과를 살펴보면, 기초값(Baseline) 대비 마지막 방문(방문5)에서 변화(Change3)의 평균이 고용량군은 5.11±4.81ml/kg/min, 저용량군은 4.20±5.49ml/kg/min, 위약군은 2.34±2.99ml/kg/min이었으며, 위약군을 제외한 두 UG0712군은 방문에 따라 수치가 통계적으로 유의하게 증가 한것으로 나타났다 (RM ANOVA, 고용량군 p=0.0002, 저용량군 0.0045). 기초값 대비 방문 3, 4, 5의 차이는 두 UG0712군이 위약군보다 전반적으로 높았으며, 이 중 고용량 대 위약군의 군간 차이가 통계적으로 유의하게 나타났다 (RM ANCOVA, p=0.0292) (표 24, 도 24).Referring to VO 2 max (maximum oxygen uptake) analysis results for the entire study population, the mean value based on the high-dose group (Baseline) compared to the last visit changes (Change3) in (Visit 5) was 5.11 ± 4.81ml / kg / min, (UG0712 group), except for the placebo group, showed a statistically significant increase with visits (RM ANOVA, high dose group, p <0.05) = 0.0002, low dose group 0.0045). The difference in baseline values between
1) Change over time: RM ANOVA 1) Change over time: RM ANOVA
2) 처치군 간 차이(Difference between treatment groups): RM ANCOVA (Dunnett's multiple comparison)2) Difference between treatment groups: RM ANCOVA (Dunnett's multiple comparison)
Change 1: Visit-기초값, Change 2: Visit 4-기초값, Change 3: Visit 5-기초값Change 1: Visit - Baseline value, Change 2: Visit 4 - Baseline value, Change 3: Visit 5 - Baseline value
개개인의 유산소성 능력은 최대 혹은 탈진 운동시 얼마나 많은 산소를 이용하여 활동을 할 수 있는가를 의미하며, 이는 VO2 max를 통해 알 수 있다. 즉, VO2 max는 각 개인의 기능적 능력이라고 할 수 있으며, 산소를 혈액으로 운반하는 폐의 능력과 심장의 혈액 펌프작용 및 펌프된 혈액이 근육으로 공급되는 과정을 알 수 있게 하는 중요한 변수이다.Individual aerobic capacity means how much oxygen can be used during maximal or exhaustive exercises, which can be determined by VO 2 max. In other words, VO 2 max is an individual's functional ability and is an important parameter that allows us to know the ability of the lung to carry oxygen to the blood and the blood pump action of the heart and how the pump blood is fed to the muscle.
실험결과, 최대 산소섭취량에 따른 유산소 운동 능력 즉, 심폐운동 지구력을 나타내는 VO2 max가 UG0712 고용량군에서 위약군과 대비하여 통계적으로 유의한 증가를 보였다 (RM ANCOVA, VO2 max p=0.0292).Result, aerobic exercise capacity according to the maximum oxygen uptake that is, the VO 2 max representing the cardiopulmonary exercise endurance was a statistically significant improvement compared with the placebo group in a statistically the UG0712 high dose group (RM ANCOVA, VO 2 max p = 0.0292).
(3) AT (anaerobic threshold)(3) AT (anaerobic threshold)
운동능력 개선 효과를 평가하기 위하여 AT (anaerobic threshold)를 측정하였다.The AT (anaerobic threshold) was measured to evaluate the effect of improving exercise capacity.
전체 피험자군 (ITT군)에 대한 AT(Anaerobic threshold) 분석결과를 살펴보면, 기초값 대비 마지막 방문에서 변화(Change3)가 고용량군은 1.63±4.18ml/kg/min, 저용량군은 0.19±3.59ml/kg/min, 위약군은 -0.01±4.74ml/kg/min이었으며, 두 UG0712군은 방문에 따라 수치가 증가하였다. 기초값 대비 방문 3, 4, 5의 차이는 두 UG0712군이 위약군보다 전반적으로 높았으며, 이 중 고용량군 대 위약군이 통계적으로 유의한 차이를 나타냈다 (RM ANCOVA, p=0.0378) (표 25, 도 25).The results of AT (Anaerobic threshold) analysis for the total subjects (ITT group) were as follows: 1.63 ± 4.18 ml / kg / min in the high dose group and 0.19 ± 3.59 ml / kg / min in the placebo group, -0.01 ± 4.74 ml / kg / min in the placebo group, and increased in the UG0712 group. The differences in baseline values between
1) Change over time: RM ANOVA 1) Change over time: RM ANOVA
2) 처치군 간 차이(Difference between treatment groups): RM ANCOVA (Dunnett's multiple comparison)2) Difference between treatment groups: RM ANCOVA (Dunnett's multiple comparison)
Change 1: Visit-기초값, Change 2: Visit 4-기초값, Change 3: Visit 5-기초값Change 1: Visit - Baseline value, Change 2: Visit 4 - Baseline value, Change 3: Visit 5 - Baseline value
AT는 운동강도가 높아짐에 따라 혈청 젖산 농도가 증가하기 시작하는 특정 시점을 말하며, AT 수준이 높으면 무산소대사가 발생하지 않고 유산소운동을 오래 지속할 수 있음을 의미한다. 즉, 자신의 운동능력 페이스에서 운동을 오래 지속할 수 있다는 의미이다.AT refers to a specific point in time when the serum lactate concentration starts to increase as the exercise intensity increases. If the AT level is high, it means that the aerobic exercise can be continued for a long time without oxygen metabolism. In other words, it means that you can exercise for a long time at your athletic performance pace.
실험결과, 무산소 역치점에 따른 유산소 운동능력을 나타내는 AT가 UG0712 고용량군에서 위약군과 대비하여 통계적으로 유의한 증가를 보였다 (AT p=0.0378).As a result, there was a statistically significant increase (AT p = 0.0378) in the UG0712 high-dose group compared with the placebo group in the AT showing the aerobic exercise capacity according to the anaerobic threshold value.
VO2 max 및 AT는 유산소운동능력, 즉 심폐지구력의 개선정도를 나타내는 각각의 독립적인 지표이다. 상기 실험결과, UG0712 고용량 투여군에서는 대조군에 비하여 VO2 max 및 AT값이 통계학적으로 유의한 정도로 증가하였으며, 이를 통해 정상성인이 UG0712 고용량(500mg/day)을 복용할 경우 유산소운동능력의 개선을 통해 운동능력 및 지구력 개선효과를 나타냄을 확인할 수 있다.VO 2 max and AT are independent indicators of aerobic exercise capacity, ie, degree of improvement in cardiopulmonary endurance. As a result, the VO 2 max and AT values were significantly increased in the UG0712 high dose group compared with the control group. Thus, when the UG0712 high dose group (500 mg / day) Exercise capacity and endurance.
(4) 안전성 테스트 (4) Safety test
1) 시험방법1) Test method
무작위 배정된 117명의 피험자 모두 UG0712 또는 위약을 섭취하고 적어도 한 번 이상의 안전성 자료를 평가할 수 있었으므로 분석에 포함되었다.All 117 randomized subjects were included in the analysis because they were able to ingest UG0712 or placebo and to evaluate at least one safety data sheet.
(a) 이상반응(a) Adverse reaction
자/타각 증상을 통한 이상반응은 시험제제 섭취 후부터 섭취 후 12주 (방문5)까지 평가하며, 이상반응이 발생한 경우에는 증례기록지에 기록하였다. 피험자의 자발적 보고 이외에도 매 방문 시 문진 등을 통하여 확인하며, 이상반응이 발생한 경우, 증상, 발생시기, 지속시간, 이상반응의 강도 및 인과관계에 대하여 증례기록지에 상세히 기록하였다. 기타 임상적으로 유의한 비정상적 임상실험실검사 및 활력징후 결과도 이상반응으로 기록/보고하였다.The adverse reactions from the symptoms were evaluated from the time of ingestion until 12 weeks after the ingestion (visit 5) and recorded in the case report when an adverse reaction occurred. In addition to the voluntary reporting of the subjects, they were checked through interviews at each visit. In case of adverse events, the symptoms, timing, duration, severity of adverse events, and causal relationship were recorded in the case report. Other clinically significant abnormal clinical laboratory tests and vital sign results were recorded / reported as adverse events.
(b) 일반소견(b) General observations
활력징후(Vital sign), 즉, 혈압(mmHg), 맥박(회/분)은 피험자가 최소 5분간 안정을 취한 후에 측정하였다. 임상실험실 검사(Laboratory test) 및 신체검사 소견(이학적 검사)은 스크리닝 방문(방문 1) 및 방문 3, 4, 5에 실시하여 기록하였다. 위 항목들에 대해 임상적으로 유의한 비정상 소견이 발생한 경우 이상반응으로 처리하여 자세히 기술하였다.Vital signs, ie, blood pressure (mmHg) and pulse (times / minute) were measured after the subjects had stabilized for at least 5 minutes. Clinical laboratory tests and physical examinations (physical examinations) were conducted at screening visits (visit 1) and visits 3, 4 and 5. If clinically significant abnormal findings were found in the above items, they were treated as adverse events and described in detail.
2) 결과2) Results
임상시험 전후 실시한 임상실험실검사, 활력징후, 신체검사가 유의한 변화를 보이지 않았고, 이상반응 발생율을 비교한 결과 치료군과 위약군간 통계적으로 유의한 차이가 없었으므로 UG0712는 안전하게 복용할 수 있는 제제로 판단된다.There was no statistically significant difference between the treatment group and the placebo group as a result of comparing the incidence of adverse reactions, and there was no significant change in clinical laboratory tests, vital signs, and physical examinations conducted before and after the clinical trial. Therefore, UG0712 was judged as a safe preparation do.
Claims (21)
상기 파낙스속 식물의 잎 추출물 가공물 중 총 진세노사이드 함량이 30wt% 이상이며,
상기 파낙스속 식물의 잎 추출물 가공물 중 Rg3, Rg5 및 Rk1 함량이 5wt% 이상인 조성물.A composition for promoting exercise capacity, fatigue recovery or antioxidation activity comprising a mixture of a leaf extract of Panax spp. And a leaf extract of Panax spp. As an active ingredient,
Wherein the total ginsenoside content in the leaf extract of the Panax plant is 30 wt% or more,
Wherein the Rg3, Rg5 and Rk1 content of the leaf extract of the Panax plant is 5 wt% or more.
(a) 파낙스속 식물의 잎을, 물, C1 -4 알코올, 및 이들의 혼합용매로 구성된 군에서 선택되는 추출 용매로 환류추출한 후, 동결건조시켜 파낙스속 식물의 잎 추출물을 수득하고,
(b) 상기 수득된 추출 분말에 물과 빙초산을 첨가하고 60~100℃에서 교반하면서 가공반응을 수행한 후 건조시켜 파낙스속 식물의 잎 추출물의 가공물을 수득하고,
(c) 상기 (a)에서 수득된 파낙스속 식물의 잎 추출물과 (b)에서 수득된 파낙스속 식물의 잎 추출물의 가공물을 혼합하여 제조하는 것을 특징으로 하는 조성물.The mixture according to claim 1, wherein the leaf extract of Panax spp. And the leaf extract of Panax spp.
(a) Leaf of a plant of the genus Panax is refluxed with an extraction solvent selected from the group consisting of water, C 1 -4 alcohol and a mixed solvent thereof, followed by lyophilization to obtain a leaf extract of a plant of the genus Panax,
(b) adding water and glacial acetic acid to the obtained extract powder, performing a processing reaction with stirring at 60 to 100 캜, and drying the resultant to obtain a leaf extract of a plant of Panax ginseng,
(c) a composition comprising the leaf extract of the Panax ginseng plant obtained in (a) and the leaf extract of the Panax ginseng plant obtained in (b).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080014887 | 2008-02-19 | ||
KR1020080014887 | 2008-02-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090013618A Division KR20090089815A (en) | 2008-02-19 | 2009-02-18 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of panax species plant leaf extract and processed panax species plant leaf extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140089502A true KR20140089502A (en) | 2014-07-15 |
Family
ID=41207875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090013618A KR20090089815A (en) | 2008-02-19 | 2009-02-18 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of panax species plant leaf extract and processed panax species plant leaf extract |
KR1020140078987A KR20140089502A (en) | 2008-02-19 | 2014-06-26 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090013618A KR20090089815A (en) | 2008-02-19 | 2009-02-18 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of panax species plant leaf extract and processed panax species plant leaf extract |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR20090089815A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101972949B1 (en) | 2017-11-28 | 2019-04-26 | 심마니산삼영농조합법인 | Composition comprising mixture of active protopanaxadiol for improve exercise capacity |
KR20200131011A (en) * | 2019-05-13 | 2020-11-23 | 문은주 | Manufacturing method for cosmetics composition comprising acid treated ginseng byproducts extracts for whitening |
WO2023106645A1 (en) * | 2021-12-08 | 2023-06-15 | 애니머스큐어 주식회사 | Composition for preventing or treating muscular diseases containing ginsenoside rg5 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101698201B1 (en) | 2010-05-20 | 2017-01-19 | (주)뉴트리 | Composition for increasing muscle mass, anti-fatigue and enhancing exercise performance comprising panduratin derivatives or Boesenbergia pandurata extract |
KR101260047B1 (en) * | 2012-05-25 | 2013-05-06 | 한국과학기술연구원 | Panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5 and rk1 produced by microwave irradiation, a process for the preparation thereof, and a composition comprising the same |
KR101741827B1 (en) | 2015-07-10 | 2017-05-31 | 한국과학기술연구원 | Pharmaceutical composition for preventing or treating skin cancer comprising Panax spp. plant extact and method for preventing or treating skin cancer in a subject using the same |
-
2009
- 2009-02-18 KR KR1020090013618A patent/KR20090089815A/en active Application Filing
-
2014
- 2014-06-26 KR KR1020140078987A patent/KR20140089502A/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101972949B1 (en) | 2017-11-28 | 2019-04-26 | 심마니산삼영농조합법인 | Composition comprising mixture of active protopanaxadiol for improve exercise capacity |
KR20200131011A (en) * | 2019-05-13 | 2020-11-23 | 문은주 | Manufacturing method for cosmetics composition comprising acid treated ginseng byproducts extracts for whitening |
WO2023106645A1 (en) * | 2021-12-08 | 2023-06-15 | 애니머스큐어 주식회사 | Composition for preventing or treating muscular diseases containing ginsenoside rg5 |
Also Published As
Publication number | Publication date |
---|---|
KR20090089815A (en) | 2009-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110052730A1 (en) | Leaves Extract of Panax sp., a Process of Making the Same and Uses Thereof | |
US9446006B2 (en) | Hydroxytyrosol combinations for enhancing mitochondrial function and energy production | |
US20210220422A1 (en) | Dietary supplement compositions and methods | |
Liu et al. | Antifatigue and increasing exercise performance of Actinidia arguta crude alkaloids in mice | |
US9011938B2 (en) | Methods and formulations for treating chronic liver disease | |
KR20140089502A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract | |
US20190191752A1 (en) | Dietary supplements and compositions for enhancing physical performance and energy levels | |
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
Wen et al. | Effects of aqueous extracts from Panax ginseng and Hippophae rhamnoides on acute alcohol intoxication: An experimental study using mouse model | |
Manosroi et al. | Potent hypoglycemic effect of Nigerian anti-diabetic medicinal plants | |
JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
Jia et al. | Evaluation of silymarin extract from Silybum marianum in mice: anti-fatigue activity | |
KR101594349B1 (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising processed Panax species plant leaf extract | |
KR101160088B1 (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
CN109157548B (en) | Composition with functions of resisting fatigue and tonifying yang and preparation method thereof | |
KR20090089813A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising panax species plant leaf extract | |
Dinku et al. | Antidiabetic activity of the leaf extracts of Pentas schimperiana subsp. schimperiana (A. Rich) Vatke on alloxan induced diabetic mice | |
Chaudhary et al. | Evaluation of antidiabetic activity of Cressa cretica Linn in alloxan induced diabetes in rats | |
Deuster et al. | Dietary Supplements and Military Divers A Synopsis for Undersea Medical Officers | |
KR20170122612A (en) | Composition and its manufacturing method for sports nutrition comprising of Trigonella foenum-graecum extract and ferulic acid | |
EP4043024A1 (en) | Composition for preventing or treating neurodegenerative diseases containing mixed herbal extract of genkwae flos, clematidis radix, and gastrodiae rhizoma | |
KR20110012696A (en) | Food composition for stress relaxation, fatigue recovery or athletic performance enhancement comprising extract of root of vitis | |
Meleshkevich et al. | BIOLOGICALLY ACTIVE SUBSTANCES IMPROVING FUNCTIONAL STATE OF LIVER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |